Remedy Ledger

Remedies › Berberine › Blood sugar and type 2 diabetes · All remedies for blood sugar and type 2 diabetes

Berberine and blood sugar and type 2 diabetes: what the evidence says

Based on the evidence, berberine lowers blood sugar modestly in type 2 diabetes, about half a point of HbA1c in pooled trials, though most trials are small, short and from China.

4/5 Moderate

At least one well-run randomized trial in people on this outcome, with a positive result. How we score

This is the best-studied use of berberine. Pooled analyses of 14 to 46 randomized trials agree that it lowers fasting glucose and HbA1c (the three-month blood sugar average): the 2022 analysis of 37 trials and 3,048 patients found HbA1c 0.63 points lower than in control groups, and a 2023 analysis limited to placebo-controlled trials found a similar effect.

The biggest single trial, 409 newly diagnosed patients at 20 Chinese hospitals, found HbA1c fell 0.99 points on berberine against 0.59 on placebo over 12 weeks. In the small head-to-head trials, berberine did about as well as metformin, but not better.

The quality of the evidence is the honest weak point. Most trials were run in China, were small and lasted three months or less, and nearly every review rated their methods low; a 2025 overview of 54 reviews rated only one as high quality. One analysis found the effect faded in trials longer than 90 days, at doses above 2 g a day and in people over 60. No trial has tested whether berberine prevents diabetes complications.

A drug made partly from berberine, berberine ursodeoxycholate (HTD1801), has now passed two large phase 3 trials, lowering HbA1c by 0.5 to 0.7 points more than placebo. That is a pharmaceutical form, not a supplement capsule.

If you take diabetes medicine, do not add berberine or swap a prescription for it without your doctor: on top of glucose-lowering drugs it can push blood sugar too low, and it changes how the liver handles several medicines.

We screened all 108 human-study records PubMed returned and read 42 abstracts in full: 21 of the 31 systematic reviews (the other 10 covered animal studies, decoctions or other diseases) and 19 of the 48 trials, choosing the largest and the placebo-controlled ones.

The evidence ladder higher rungs count for more
  1. Meta-analyses of trialspooled randomized trials8
  2. Human studiestrials and population studies10
  3. Case reportssingle people0
  4. Animal studiesmostly rodents346
  5. Lab studiescells, test tubes152

The studies in people, read one by one

ResultTypeWhat they didWhat they found
PositiveSystematic review / meta-analysis, 2022
3,048 people		Meta-analysis of 37 randomized trials in type 2 diabetes (English and Chinese databases)
Measured: HbA1c, fasting glucose, low blood sugar		HbA1c -0.63 points (95% CI -0.72 to -0.53), fasting glucose -0.82 mmol/L; risk of low blood sugar not significantly raised (RR 0.48, 95% CI 0.21 to 1.08). PubMed 36467075
PositiveSystematic review / meta-analysis, 2023
1,761 people		Meta-analysis of 20 placebo-controlled randomized trials (University of Hong Kong, registered in PROSPERO)
Measured: Fasting glucose, HbA1c, insulin resistance		Fasting glucose -0.52 mmol/L (95% CI -0.72 to -0.33); HbA1c -4.48 mmol/mol (7 trials); larger effects in women, people with diabetes and Asians. PubMed 37598753
PositiveSystematic review / meta-analysis, 2021Meta-analysis of 46 randomized trials, berberine alone or added to standard diabetes treatment
Measured: HbA1c, fasting glucose, lipids		HbA1c -0.73 (95% CI -0.97 to -0.51); fasting glucose -0.86; also lower triglycerides and LDL. PubMed 34956436
PositiveSystematic review / meta-analysis, 2019
2,313 people		Meta-analysis of 28 randomized trials in type 2 diabetes
Measured: Fasting and after-meal glucose, HbA1c		Fasting glucose -0.54 mmol/L; HbA1c lower; the effect became unremarkable after 90 days, above 2 g a day and over age 60. PubMed 30393248
PositiveSystematic review / meta-analysis, 2012
1,068 people		Meta-analysis of 14 randomized trials
Measured: Blood sugar and lipids		Better than lifestyle change alone; not better than metformin, glipizide or rosiglitazone; methodological quality generally low. PubMed 23118793
PositiveSystematic review / meta-analysis, 2015
2,569 people		Meta-analysis of 27 randomized trials (diabetes, cholesterol and blood pressure)
Measured: Fasting glucose, after-meal glucose, HbA1c		Lower glucose than lifestyle change or placebo, no difference from diabetes pills; authors call the included studies of limited quality. PubMed 25498346
PositiveSystematic review / meta-analysis, 2026Meta-analysis of more than 30 trials of probiotics, synbiotics and berberine in type 2 diabetes
Measured: Fasting glucose, HbA1c		Pooled reductions were modest: fasting glucose -0.71 mmol/L and HbA1c -0.19 points, with large differences between studies. PubMed 42213651
PositiveSystematic review / meta-analysis, 2025Overview of 54 systematic reviews of berberine trials, quality graded with AMSTAR-2 and GRADE
Measured: Quality of the evidence		Berberine improved 25 of 27 type 2 diabetes outcomes, but only 1 review was high quality, 8 low and 45 critically low. PubMed 40269802
PositiveRandomized trial, 2020
409 people		Randomized, double-blind, placebo-controlled, 20 hospitals in China, newly diagnosed type 2 diabetes, 12 weeks (PREMOTE)
Measured: HbA1c		HbA1c -0.99 points on berberine vs -0.59 on placebo (P < 0.001); more stomach and bowel side effects on berberine. PubMed 33024120
PositiveRandomized trial, 2021
297 people		Randomized, double-blind, multicenter, 16 weeks, newly diagnosed high blood sugar (berberine, Bifidobacterium, both, placebo)
Measured: Fasting glucose		Fasting glucose -0.50 mmol/L vs placebo (95% CI -0.85 to -0.15); a clear HbA1c drop was seen only with the combination. PubMed 34365978
PositiveRandomized trial, 2008
116 people		Randomized, placebo-controlled, 1 g a day for 3 months, type 2 diabetes with high cholesterol
Measured: Glucose, HbA1c, lipids		HbA1c fell from 7.5% to 6.6% and fasting glucose from 7.0 to 5.6 mmol/L, both significantly more than placebo (P < 0.0001); mild constipation in 5. PubMed 18397984
PositiveRandomized trial, 2008
84 people		Randomized vs metformin (36 patients) plus an uncontrolled add-on study (48 patients), 3 months
Measured: HbA1c, fasting glucose		Effect similar to metformin; HbA1c 9.5% to 7.5% on berberine; 34.5% had passing stomach and bowel side effects. PubMed 18442638
PositiveRandomized trial, 2023
34 people		Randomized, double-blind, placebo-controlled, prediabetes, 500 mg three times daily for 12 weeks (branded extract)
Measured: Fasting glucose, HbA1c		Fasting glucose 6.75 to 5.33 mmol/L and HbA1c 6.40% to 5.43%; significant against placebo. PubMed 37679692
PositiveRandomized trial, 2023
49 people		Randomized, double-blind, placebo-controlled, overweight adults with high fasting glucose, berberine phytosome for 2 months (Italy)
Measured: Fasting glucose		Glucose and insulin fell more than with placebo (glycemia P = 0.004). PubMed 37522683
PositiveRandomized trial, 2025Randomized, double-blind, placebo-controlled, type 2 diabetes, berberine 1,200 mg plus cinnamon 600 mg for 12 weeks (Iran)
Measured: Fasting glucose, HbA1c		Fasting glucose (P = 0.031) and HbA1c (P = 0.013) lower than placebo; berberine combined with cinnamon, so the share of each is unknown. PubMed 39998703
PositiveRandomized trial, 2026
407 people		Phase 3, randomized, placebo-controlled, HTD1801 (berberine ursodeoxycholate, a drug form) alone, 24 weeks
Measured: HbA1c		HbA1c -1.3 points vs -0.6 on placebo (difference -0.7, 95% CI -0.8 to -0.5); diarrhoea 9.6% vs 0.7%. PubMed 42635552
PositiveRandomized trial, 2026
549 people		Phase 3, randomized, placebo-controlled, HTD1801 added to metformin, 24 weeks
Measured: HbA1c		Difference vs placebo -0.5 points (95% CI -0.7 to -0.4); diarrhoea 23.8% vs 1.1%; no severe low blood sugar. PubMed 42251702
PositiveRandomized trial, 2025
113 people		Phase 2, randomized, placebo-controlled, HTD1801 for 12 weeks
Measured: HbA1c		HbA1c -0.4 (500 mg twice daily) and -0.7 points (1,000 mg twice daily) vs placebo. PubMed 40029660

Where the sources agree, and where they don’t

3 of 7 kinds of source point toward a benefit, 2 toward no effect or harm, 1 are mixed, and 1 has no data yet. Agreement between independent kinds of evidence matters more than the number of papers in any one of them.

Kind of sourcePoints toDetail
Meta-analyses of trialsPositiveHbA1c about 0.5-0.7 lower; quality mostly rated low
Large placebo-controlled trialsPositive409 and 297 people in China
Drug form HTD1801 (phase 3)PositiveHbA1c 0.5-0.7 lower, 956 people
Head-to-head with metforminNo effectabout equal, not better
Prevention trial (2,024 people)No dataresults due after 2026
FDA reportsNegative4 blood-sugar reports, 1 hospital stay for low blood sugar
Public reportsMixed14 of 27 say it helped; 4 stopped over gut pain or diarrhoea

Beyond Google: 12 findings about Berberine from trial registries, FDA reports and patent offices that a normal search rarely shows. See them

What people report

We read public first-person posts and counted every outcome, good or bad. 27 reports about this condition, read on 2026-10-28; 6 mention side effects.

  • 14Helped
  • 5No effect
  • 4Got worse
  • 3Mixed
  • 1Too early

Why these counts prove nothing on their own: people who post are not a random sample, most take other treatments at the same time, and nobody checks the diagnosis. We show them because they tell researchers what to test next.

Read all 27 reports
  • Helped Within about a week, after-meal readings were near 131 instead of 180-210 and morning readings fell from the 140s to the 120s. Diabetes.co.uk forum, 2023-12-16 (Only one week in; started cinnamon at the same time; planned to check with doctor because of heart medicines.)
  • Worse After two weeks developed severe pain across the upper abdomen that stopped within 48 hours of quitting; a later report mentions stomach ache again. Side effects: severe upper abdominal pain. Diabetes.co.uk forum, 2023-12-16 (Poster attributes the pain to berberine because nothing else changed; no glucose result given.)
  • Mixed A first brand made little difference and an HbA1c check was only slightly better; a later refrigerated brand seemed to bring readings into the 4s. Diabetes.co.uk forum, 2024-11-23 (Already in non-diabetic range; poster calls the first try inconclusive and possibly natural progress.)
  • Helped After four months with bitter melon, halved diabetes medicine and was still having low blood sugar episodes. Side effects: low blood sugar episodes (hypos) while on gliclazide. Diabetes.co.uk forum, 2024-12-30 (Two supplements started together; the hypos happened alongside a sulfonylurea, the combination doctors warn about.)
  • No effect Took it with every meal but could not tell how much it helped and it did not fix morning highs; metformin later worked far better. Diabetes.co.uk forum, 2024-08-12 (Poster judges berberine at most a small help; no numbers for the berberine period.)
  • Worse Stopped after one week at 1,500 mg a day because of intestinal pain; fasting glucose was unchanged; later attempts caused the same pain. Side effects: intestinal pain. Diabetes.co.uk forum, 2023-10-18 (Only one week of glucose data; an earlier attempt was interrupted by diverticulitis.)
  • No effect Switched from metformin because of side effects; berberine had no side effects but, like metformin, barely moved fasting glucose. Diabetes.co.uk forum, 2024-08-13 (Poster says HbA1c is hard to attribute because they use several measures at once.)
  • Helped Takes it twice a day and thinks it helps; most recent HbA1c was 39 mmol/mol, in the normal range. Diabetes.co.uk forum, 2024-08-22 (No before value or duration given.)
  • Worse Fine for a day, then severe stomach pain and diarrhoea worse than on metformin, so stopped; now controls glucose with diet. Side effects: severe diarrhoea, stomach pain. Diabetes.co.uk forum, 2024-05-02 (Short trial; no glucose result.)
  • No effect Took two capsules a day for a while; any lowering of glucose was marginal and not worth it next to free metformin. Diabetes.co.uk forum, 2024-05-17 (Poster says it may have helped slightly.)
  • Mixed Berberine alone did not work; after adding black seed oil, walking and fewer carbs, glucose became responsive. Quit twice early on from gut discomfort. Side effects: intestinal discomfort at the start. Diabetes.co.uk forum, 2023-09-26 (Several changes at once; no after value for HbA1c.)
  • Worse After a couple of months it caused persistent diarrhoea, worse than standard metformin; will not try again. Side effects: chronic diarrhoea. Diabetes.co.uk forum, 2023-10-19 (No glucose result given.)
  • Helped Used it for about a year and thinks it helped blood sugar; stopped over worries about long-term effects on gut bacteria. Diabetes Daily forum, 2025-07-18 (No numbers.)
  • No effect Took three different brands for months at a time and saw no improvement in blood glucose or anything else. Diabetes Daily forum, 2025-07-22 (Brands not tested for content.)
  • Helped About a week in, cut metformin to 500 mg and readings stayed in the 80s and low 90s; later said it beats metformin for them. Diabetes Daily forum, 2020-07-25 (Short time frame; another member notes the poster had lost weight and was mildly diabetic.)
  • Helped Could not take metformin; has taken 1,500 mg a day for years with no side effects and sees higher readings when a dose is missed. Diabetes Daily forum, 2019-11-26 (Posted across several threads 2016-2020; no lab values.)
  • Mixed Took it from October 2019; it worked somewhat but readings never fell below 195, and it stopped working after a few months. Diabetes Daily forum, 2020-07-29 (No baseline given.)
  • Helped Average fasting glucose fell from 144 to 106 within about two weeks; a year later, on metformin too, still felt it helped. Diabetes Daily forum, 2020-07-30 (Cinnamon started at the same time; poster says they cannot prove it.)
  • Helped With 500 mg three times daily and a diet change, HbA1c fell from 8.1% to 6.3% in three months, then 5.6%; lost 25 lb. Diabetes Daily forum, 2015-09-11 (Diet changed at the same time; another member questioned whether this new account was promoting a brand.)
  • No effect Took a generic brand for three months and saw no change in blood glucose. Diabetes Daily forum, 2016-01-04 (Brand not tested; later planned to try another brand.)
  • Helped Has gone on and off it and says it clearly cuts morning glucose release and improves after-meal readings after a few weeks. Diabetes Daily forum, 2016-01-16 (No numbers; long-time advocate in that forum.)
  • Too early A few days in, a fasting reading was 86 and after-meal numbers looked lower than before. Diabetes Daily forum, 2016-01-19 (Only days of use; vinegar taken too.)
  • Helped Replaced metformin with berberine plus a ketogenic diet; reports good glucose numbers and visible weight loss. Diabetes Daily forum, 2018-04-07 (Diet change is a large confounder; no lab values.)
  • Helped A multi-ingredient product containing berberine lowered readings by about 30-40 points on days taken; weight did not change. Diabetes Daily forum, 2019-11-26 (Product is a blend, so berberine's share is unknown.)
  • Helped Takes a low dose with other herbs; says it boosts metformin so less is needed, and manages diabetes with herbs, diet and exercise. City-Data forum, 2019-07-07 (Several herbs at once; no numbers.)
  • Helped Replaced metformin with 1,200 mg a day plus diet; HbA1c 5.6%, the same as on metformin; also stopped a blood-pressure pill. City-Data forum, 2021-11-01 (Single HbA1c value; stopping a blood-pressure medicine was the poster's own choice.)
  • Helped With diet, exercise, stress and sleep changes plus berberine, HbA1c fell from 14 to 8 in a year; metformin and glipizide had not suited. City-Data forum, 2022-01-28 (Many changes at once; berberine's share unknown.)

Every other paper we found

PubMed returned 767 papers for this search on 2026-10-28. We read the human studies above ourselves. The rest are sorted by type automatically from PubMed's labels, which are sometimes wrong. We removed 14 papers that only share a word with this search.

Animal studies 346
  1. Hepatorenal protective effect of berberine-loaded Ag-ZnO nanoparticles in mitigating carbon tetrachloride (direct) and alloxan-induced oxidative stress (indirect) in albino rat models. RSC Adv, 2026
  2. Effect of Berberine on Improving Reproduction Disorder in Female Mice with Type 2 Diabetes Mellitus. Chin J Integr Med, 2026
  3. Zhimu-Huangbo herb pair ameliorates diabetic cognitive impairment by modulating the CCL3-CCR5 axis-dependent interaction between neurons and CD8+ T cells. Phytomedicine, 2026
  4. The Beneficial Effects of Berberine on Vascular Dysfunction in Type 2 Diabetes Are Enhanced by HSP70 Inhibition. Biomolecules, 2026
  5. Supra-additive neuroprotective effects of berberine-metformin combination in diabetic encephalopathy: Chou-Talalay synergy quantification, AMPK-Nrf2 axis modulation, and pharmacokinetic verification. Metab Brain Dis, 2026
  6. Berberine attenuates hyperglycemia induced neurodegeneration in mice by modulation of Nrf2 expression. Mol Biol Rep, 2026
  7. Protective effects of Fraxinus xanthoxyloides bark in alloxan-induced diabetic rats: A phytochemical and pharmacological approach. PLoS One, 2026
  8. Preparation of berberine micelles and its anti-skin damage in hyperglycemia mice. Xenobiotica, 2026
  9. The effect(s) of berberine from Berberis vulgaris L. (Berberidaceae) on treating type 1 diabetes mellitus in streptozotocin-induced diabetic rats. Iran J Basic Med Sci, 2026
  10. Targeting the PI3K/Akt/mTOR and Nrf2 signaling axis with berberine: a novel strategy for attenuating diabetic cardiomyopathy. Naunyn Schmiedebergs Arch Pharmacol, 2026
  11. Chitosan-Based Thermosensitive Hydrogel Codelivering Berberine and Resveratrol Promotes Wound Healing of Bacterial Infection in Diabetic Mice. ACS Appl Bio Mater, 2026
  12. Identification of novel bioactive constituents from traditional decoction of jiao-tai-Wan based on "co-decoction reaction" and comparative analysis with formula granules. J Chromatogr B Analyt Technol Biomed Life Sci, 2026
  13. Coptisine alleviates insulin resistance by suppressing SMARCE1-mediated glycolysis. Biochem Biophys Res Commun, 2026
  14. Nano-liposomal berberine and vildagliptin combination: A novel therapeutic approach against oxidative stress, inflammation, autophagy dysregulation, and fibrosis in diabetic nephropathy. Tissue Cell, 2026
  15. Berberine Alleviates Pancreatic β-Cell Ferroptosis and Injury in db/db Mice by Regulating the AGE/RAGE Pathway: Insight from Proteomic Analysis. Curr Med Sci, 2026
  16. Berberine and N-Acetylcysteine ameliorate diabetes-induced hippocampal damage by inhibiting apoptosis and neuroinflammation, and improve synaptic plasticity in rats. J Mol Histol, 2026
  17. Jiangtang Tiaozhi formula improves obesity and insulin resistance by inhibiting skeletal muscle inflammation and pyroptosis in diet-induced obese mice. Phytomedicine, 2026
  18. Demethyleneberberine attenuates combined cognitive and metabolic dysfunctions in an insulin-resistance-induced Alzheimer's disease rat model: Synthesis, in-silico and in-vivo insights. Exp Neurol, 2026
  19. Comparative Pharmacokinetics and Tissue Distribution of Berberine From Bile-Processed Coptidis Rhizoma in Type 2 Diabetic Rats. Chem Biodivers, 2026
  20. Coptidis Rhizome alleviates dexamethasone- and fructose-induced metabolic disorder in rats as an inducer of HO-1 agonist via erythrocyte metabolism. J Ethnopharmacol, 2026
  21. Protective effects of berberine-loaded chitosan/solid lipid nanoparticles in streptozotocin-induced gestational diabetes mellitus rats. Exp Biol Med (Maywood), 2025
  22. Berberine ameliorates acute hyperglycemia and hypoinsulinemia induced by ketamine/xylazine in rats: role of alpha2 adrenergic receptors, oxidative stress and inflammatory suppressing mechanisms. BMC Vet Res, 2025
  23. Coptisine alleviates high glucose-induced HUVEC dysfunction in vitro and inhibits gestational diabetes mellitus in vivo. J Mol Histol, 2025
  24. Berberine nanoemulsion attenuates bisphenol A-induced metabolic impairment through NF-κB signaling in the liver of rat. Toxicol Rep, 2025
  25. Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis. Pharmacol Res, 2025
  26. Role of berberine in metabolic and bone changes in ovariectomized rats. Arch Physiol Biochem, 2025
  27. Berberine attenuates obesity-induced skeletal muscle atrophy via regulation of FUNDC1 in skeletal muscle of mice. Sci Rep, 2025
  28. Epiberberine Improves Hyperglycemia and Ameliorates Insulin Sensitivity in Type 2 Diabetic Mice. Nephrology (Carlton), 2025
  29. Berberine Improves Glucose and Lipid Metabolism in Obese Mice Through the Reduction of IRE1/GSK-3β Axis-Mediated Inflammation. Endocr Metab Immune Disord Drug Targets, 2025
  30. Unveiling nature's antidiabetic potential in Berberis orthobotrys seeds for alloxan-induced diabetic rats. Sci Rep, 2025
  31. Gegen Qinlian Decoction inhibits liver ferroptosis in type 2 diabetes mellitus models by targeting Nrf2. J Ethnopharmacol, 2025
  32. Potentiation and in vivo evaluation of anti-obesity activity of berberine through encapsulation in guar-acacia gum nanocomplexes. Naunyn Schmiedebergs Arch Pharmacol, 2025
  33. Berberine alleviates AGEs-induced ferroptosis by activating NRF2 in the skin of diabetic mice. Exp Biol Med (Maywood), 2024
  34. Nanocarrier-Assisted Delivery of Berberine Promotes Diabetic Alveolar Bone Regeneration by Scavenging ROS and Improving Mitochondrial Dysfunction. Int J Nanomedicine, 2024
  35. [Mechanism of berberine in improving adipocytic IR by mediating BMAL1:CLOCK complex and regulating glucose and lipid metabolism]. Zhongguo Zhong Yao Za Zhi, 2024
  36. Effect of berberine combined with metformin on autophagy in polycystic ovary syndrome by regulating AMPK/AKT/mTOR pathway. Mol Reprod Dev, 2024
  37. Involvement of Sirt1-FoxO3a-Bnip3 axis and autophagy mediated mitochondrial turnover in according protection to hyperglycemic NRK-52E cells by Berberine. Toxicol In Vitro, 2024
  38. Specific Compounds Derived from Traditional Chinese Medicine Ameliorate Lipid-Induced Contractile Dysfunction in Cardiomyocytes. Int J Mol Sci, 2024
  39. Preventive effects of a nutraceutical mixture of berberine, citrus and apple extracts on metabolic disturbances in Zucker fatty rats. PLoS One, 2024
  40. Comprehensive insights into berberine's hypoglycemic mechanisms: A focus on ileocecal microbiome in db/db mice. Heliyon, 2024
  41. Characterizing and identifying of miRNAs involved in berberine modulating glucose metabolism of Megalobrama amblycephala. Fish Physiol Biochem, 2024
  42. Ge-Gen-Qin-Lian decoction alleviates the symptoms of type 2 diabetes mellitus with inflammatory bowel disease via regulating the AGE-RAGE pathway. BMC Complement Med Ther, 2024
  43. Berberine improves cognitive impairment by alleviating brain atrophy and promoting white matter reorganization in diabetic db/db mice: a magnetic resonance imaging-based study. Metab Brain Dis, 2024
  44. The combination of berberine and isoliquiritigenin synergistically improved adipose inflammation and obesity-induced insulin resistance. Phytother Res, 2024
  45. Berberine attenuates obesity-induced insulin resistance by inhibiting miR-27a secretion. Diabet Med, 2024
  46. BBR affects macrophage polarization via inhibition of NF-κB pathway to protect against T2DM-associated periodontitis. J Periodontal Res, 2024
  47. Beneficial Effects of Natural Alkaloids from Berberis glaucocarpa as Antidiabetic Agents: An In Vitro, In Silico, and In Vivo Approach. ACS Omega, 2024
  48. A Dual Therapeutic Approach to Diabetes Mellitus via Bioactive Phytochemicals Found in a Poly Herbal Extract by Restoration of Favorable Gut Flora and Related Short-Chain Fatty Acids. Appl Biochem Biotechnol, 2024
  49. Activation of NRF2 by epiberberine improves oxidative stress and insulin resistance in T2DM mice and IR-HepG2 cells in an AMPK dependent manner. J Ethnopharmacol, 2024
  50. Berberine Metabolites Stimulate GLP-1 Secretion by Alleviating Oxidative Stress and Mitochondrial Dysfunction. Am J Chin Med, 2024
  51. Berberine attenuates cognitive dysfunction and hippocampal apoptosis in rats with prediabetes. Chem Biol Drug Des, 2024
  52. Uncovering the key pharmacodynamic material basis and possible molecular mechanism of Xiaoke formulation improve insulin resistant through a comprehensive investigation. J Ethnopharmacol, 2024
  53. Exploring the molecular mechanism of berberine for treating diabetic nephropathy based on network pharmacology. Int Immunopharmacol, 2024
  54. Berberine ameliorates glucocorticoid-induced hyperglycemia: an in vitro and in vivo study. Naunyn Schmiedebergs Arch Pharmacol, 2024
  55. [Excretion of three alkaloids from Simiao Pills in urine, feces, and bile between normal and type 2 diabetic rats]. Zhongguo Zhong Yao Za Zhi, 2023
  56. Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis. Biochem Pharmacol, 2023
  57. Simulated weightlessness induces hippocampal insulin resistance and cognitive impairment. Life Sci, 2023
  58. A novel berberine derivative targeting adipocyte differentiation to alleviate TNF-α-induced inflammatory effects and insulin resistance in OP9 cells. Biomed Pharmacother, 2023
  59. Simultaneous Administration of Berberine and Transplantation of Endometrial Stem Cell-Derived Insulin Precursor Cells on a Nanofibrous Scaffold to Treat Diabetes Mellitus in Mice. Mol Neurobiol, 2023
  60. Ameliorative effects of the Coptis inflorescence extract against lung injury in diabetic mice by regulating AMPK/NEU1 signaling. Phytomedicine, 2023
  61. Berberine enhances the function of db/db mice islet β cell through GLP-1/GLP-1R/PKA signaling pathway in intestinal L cell and islet α cell. Front Pharmacol, 2023
  62. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. Biomed Pharmacother, 2023
  63. Antidiabetic activity of Berberis brandisiana is possibly mediated through modulation of insulin signaling pathway, inflammatory cytokines and adipocytokines in high fat diet and streptozotocin-administered rats. Front Pharmacol, 2023
  64. Investigation of the material basis of Xiexin Tang to alleviate type 2 diabetes mellitus based on spectrum-effect analysis by UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci, 2023
  65. High fructose-induced skeletal muscle insulin resistance could be alleviated by berberine via AMPD1 and ADSL. Food Chem Toxicol, 2023
  66. Benefits of Huang Lian mediated by gut microbiota on HFD/STZ-induced type 2 diabetes mellitus in mice. Front Endocrinol (Lausanne), 2023
  67. Metabolic profiling integrated with pharmacokinetics to reveal the material basis of Xiaokeyinshui extract combination in the treatment of type 2 diabetes in rats. J Pharm Biomed Anal, 2023
  68. Jatrorrhizine ameliorates Schwann cell myelination via inhibiting HDAC3 ability to recruit Atxn2l for regulating the NRG1-ErbB2-PI3K-AKT pathway in diabetic peripheral neuropathy mice. Phytother Res, 2023
  69. Anti-obesity and Gut Microbiota Modulation Effect of Astragalus Polysaccharides Combined with Berberine on High-Fat Diet-Fed Obese Mice. Chin J Integr Med, 2023
  70. Paliperidone-Induced Acute Hyperglycemia Is Caused by Adrenaline Secretion via the Activation of Hypothalamic AMP-Activated Protein Kinase. Biol Pharm Bull, 2022
  71. Tissue distribution and integrated pharmacokinetic properties of major effective constituents of oral Gegen-Qinlian decoction in mice. Front Pharmacol, 2022
  72. Berberine mitigates hepatic insulin resistance by enhancing mitochondrial architecture via the SIRT1/Opa1 signalling pathway. Acta Biochim Biophys Sin (Shanghai), 2022
  73. Berberine supplementation modulates the somatotropic axis and ameliorates glucose tolerance in dairy goats during late gestation and early lactation. BMC Vet Res, 2022
  74. In Vitro and In Vivo Sucrosomial® Berberine Activity on Insulin Resistance. Nutrients, 2022
  75. [Effects of berberine on LPS /NF-κB and MAPK signaling pathways in PCOS model rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2022
  76. Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats. Drug Deliv, 2022
  77. Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARα in ApoE-/- mice. Biochem Biophys Res Commun, 2022
  78. Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain. Pharmaceuticals (Basel), 2022
  79. Berberine ameliorates mesenteric vascular dysfunction by modulating perivascular adipose tissue in diet-induced obese in rats. BMC Complement Med Ther, 2022
  80. Berberine Ameliorates Insulin Resistance by Inhibiting IKK/NF-κB, JNK, and IRS-1/AKT Signaling Pathway in Liver of Gestational Diabetes Mellitus Rats. Metab Syndr Relat Disord, 2022
  81. A New Berberine Preparation Protects Pancreatic Islet Cells from Apoptosis Mediated by Inhibition of Phospholipase A2/p38 MAPK Pathway. Bull Exp Biol Med, 2022
  82. Jatrorrhizine from Rhizoma Coptidis exerts an anti-obesity effect in db/db mice. J Ethnopharmacol, 2022
  83. Modulation of Gut Microbiota and Metabolites by Berberine in Treating Mice With Disturbances in Glucose and Lipid Metabolism. Front Pharmacol, 2022
  84. Berberis dictyophylla F. inhibits angiogenesis and apoptosis of diabetic retinopathy via suppressing HIF-1α/VEGF/DLL-4/Notch-1 pathway. J Ethnopharmacol, 2022
  85. Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway In Vivo and In Vitro. Front Pharmacol, 2022
  86. In vitro and in vivo hypoglycemia effect of oxyberberine, a novel HO-1 agonist: A renewed evidence linking HO-1 to diabetes mellitus. Phytomedicine, 2022
  87. Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice. Phytomedicine, 2022
  88. Huangbai liniment and berberine promoted wound healing in high-fat diet/Streptozotocin-induced diabetic rats. Biomed Pharmacother, 2022
  89. Berberine reduces hepatic ceramide levels to improve insulin resistance in HFD-fed mice by inhibiting HIF-2α. Biomed Pharmacother, 2022
  90. Berberine Modulates Macrophage Activation by Inducing Glycolysis. J Immunol, 2022
  91. Alleviation of Diabetic Tendon Injury via Activation of Tendon Fibroblasts Autophagy under Berberine Treatment. J Vis Exp, 2022
  92. Shenlian (SL) Decoction, a Traditional Chinese Medicine Compound, May Ameliorate Blood Glucose via Mediating the Gut Microbiota in db/db Mice. J Diabetes Res, 2022
  93. Integrating network pharmacology and non-targeted metabolomics to explore the common mechanism of Coptis Categorized Formula improving T2DM zebrafish. J Ethnopharmacol, 2022
  94. Berberine ameliorates erectile dysfunction in rats with streptozotocin-induced diabetes mellitus through the attenuation of apoptosis by inhibiting the SPHK1/S1P/S1PR2 and MAPK pathways. Andrology, 2022
  95. Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3. Acta Pharmacol Sin, 2022
  96. Berberine Ameliorates Glucose Metabolism in Diabetic Rats through the alpha7 Nicotinic Acetylcholine Receptor-Related Cholinergic Anti-Inflammatory Pathway. Planta Med, 2022
  97. Berberine alleviates monosodium glutamate induced postnatal metabolic disorders associated vascular endothelial dysfunction in newborn rats: possible role of matrix metalloproteinase-1. Arch Physiol Biochem, 2022
  98. Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice. Int J Mol Sci, 2021
  99. The effect and mechanism of Jiao-tai-wan in the treatment of diabetes mellitus with depression based on network pharmacology and experimental analysis. Mol Med, 2021
  100. Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation. Pharm Res, 2021
  101. Synergetic protective effect of berberine and ginsenoside Rb1 against tumor necrosis factor alpha-induced inflammation in adipocytes. Bioengineered, 2021
  102. WJCPR11 reverses the TNF-α-induced inhibition of adipocyte differentiation and glucose uptake. Biochem Biophys Res Commun, 2021
  103. Berberine Improves the Symptoms of DHEA-Induced PCOS Rats by Regulating Gut Microbiotas and Metabolites. Gynecol Obstet Invest, 2021
  104. Berberine combined with stachyose improves glycometabolism and gut microbiota through regulating colonic microRNA and gene expression in diabetic rats. Life Sci, 2021
  105. [Effect of intestinal flora changes on pharmacokinetics of astragaloside Ⅳ]. Zhongguo Zhong Yao Za Zhi, 2021
  106. Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway. Int J Biol Sci, 2021
  107. Blood-Glucose-Lowering Effect of Coptidis Rhizoma Extracts From Different Origins via Gut Microbiota Modulation in db/db Mice. Front Pharmacol, 2021
  108. Effects of Berberine on Diabetes and Cognitive Impairment in an Animal Model: The Mechanisms of Action. Am J Chin Med, 2021
  109. Berberine and Ginsenoside Rb1 Ameliorate Depression-Like Behavior in Diabetic Rats. Am J Chin Med, 2021
  110. Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. Front Endocrinol (Lausanne), 2021
  111. Amphiphilic block versus random copolymer nanoparticles with reactive oxygen species responsiveness as berberine vehicles. J Biomater Sci Polym Ed, 2021
  112. Amelioration of diabetic retinopathy in db/db mice by treatment with different proportional three active ingredients from Tibetan medicine Berberis dictyophylla F. J Ethnopharmacol, 2021
  113. In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications. J Ethnopharmacol, 2021
  114. The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice. Nutrients, 2021
  115. Berberine prevents diabetic retinopathy through inhibiting HIF-1α /VEGF/ NF-κ B pathway in db/db mice. Pharmazie, 2021
  116. Effects of berberine on cholinesterases and monoamine oxidase activities, and antioxidant status in the brain of streptozotocin (STZ)-induced diabetic rats. J Basic Clin Physiol Pharmacol, 2021
  117. Effect of berberine on hyperglycaemia and gut microbiota composition in type 2 diabetic Goto-Kakizaki rats. World J Gastroenterol, 2021
  118. Protective effects of berberine in a rat model of polycystic ovary syndrome mediated via the PI3K/AKT pathway. J Obstet Gynaecol Res, 2021
  119. Berberine elevates mitochondrial membrane potential and decreases reactive oxygen species by inhibiting the Rho/ROCK pathway in rats with diabetic encephalopathy. Mol Pain, 2021
  120. Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathway. Phytomedicine, 2021
  121. Co-administration of berberine/gypenosides/bifendate ameliorates metabolic disturbance but not memory impairment in type 2 diabetic mice. Heliyon, 2021
  122. Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways. Biomed Pharmacother, 2021
  123. Efficacy of Huanglian root decoction on kidney injury in rat's model of metabolic syndrome. J Tradit Chin Med, 2021
  124. Berberine ameliorates ovariectomy-induced anxiety-like behaviors by enrichment in equol generating gut microbiota. Pharmacol Res, 2021
  125. An integrated network pharmacology and transcriptomic method to explore the mechanism of the total Rhizoma Coptidis alkaloids in improving diabetic nephropathy. J Ethnopharmacol, 2021
  126. Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis. Reprod Biol Endocrinol, 2021
  127. The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis. Drug Metab Dispos, 2021
  128. Macrovascular Protecting Effects of Berberine through Anti-inflammation and Intervention of BKCa in Type 2 Diabetes Mellitus Rats. Endocr Metab Immune Disord Drug Targets, 2021
  129. Jateorhizine alleviates insulin resistance by promoting adipolysis and glucose uptake in adipocytes. J Recept Signal Transduct Res, 2021
  130. Berberine improves intralipid-induced insulin resistance in murine. Acta Pharmacol Sin, 2021
  131. [Effect of berberine on insulin resistance in diabetic rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2020
  132. Berberine for Appetite Suppressant and Prevention of Obesity. Biomed Res Int, 2020
  133. Antidiabetic Effects of Gegen Qinlian Decoction via the Gut Microbiota Are Attributable to Its Key Ingredient Berberine. Genomics Proteomics Bioinformatics, 2020
  134. Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice. Biomed Pharmacother, 2020
  135. Stachyose Improves the Effects of Berberine on Glucose Metabolism by Regulating Intestinal Microbiota and Short-Chain Fatty Acids in Spontaneous Type 2 Diabetic KKAy Mice. Front Pharmacol, 2020
  136. Berberine protects against diabetic retinopathy by inhibiting cell apoptosis via deactivation of the NF‑κB signaling pathway. Mol Med Rep, 2020
  137. Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids. Biomed Pharmacother, 2020
  138. Berberine Improves Inflammatory Responses of Diabetes Mellitus in Zucker Diabetic Fatty Rats and Insulin-Resistant HepG2 Cells through the PPM1B Pathway. J Immunol Res, 2020
  139. Berberine ameliorates rats model of combined Alzheimer's disease and type 2 diabetes mellitus via the suppression of endoplasmic reticulum stress. 3 Biotech, 2020
  140. Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance via reduction in association of the Glucocorticoid Receptor with phosphatidylinositol-3-kinase. Int J Biol Sci, 2020
  141. Xiaokeyinshui extract combination, a berberine-containing agent, exerts anti-diabetic and renal protective effects on rats in multi-target mechanisms. J Ethnopharmacol, 2020
  142. Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway. Curr Med Sci, 2020
  143. 1H NMR-Based Metabolomics Coupled With Molecular Docking Reveal the Anti-Diabetic Effects and Potential Active Components of Berberis vernae on Type 2 Diabetic Rats. Front Pharmacol, 2020
  144. Metformin and Berberine suppress glycogenolysis by inhibiting glycogen phosphorylase and stabilizing the molecular structure of glycogen in db/db mice. Carbohydr Polym, 2020
  145. ATP reduces mitochondrial MECR protein in liver of diet-induced obese mice in mechanism of insulin resistance. Biosci Rep, 2020
  146. Berberine attenuates fructose-induced insulin resistance by stimulating the hepatic LKB1/AMPK/PGC1α pathway in mice. Pharm Biol, 2020
  147. MgAl monolayer hydrotalcite increases the hypoglycemic effect of berberine by enhancing its oral bioavailability. Biomed Pharmacother, 2020
  148. Synthesis of disaccharide modified berberine derivatives and their anti-diabetic investigation in zebrafish using a fluorescence-based technology. Org Biomol Chem, 2020
  149. Highly bioavailable berberine formulation ameliorates diabetic nephropathy through the inhibition of glomerular mesangial matrix expansion and the activation of autophagy. Eur J Pharmacol, 2020
  150. Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. Oxid Med Cell Longev, 2020
  151. Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice. Phytother Res, 2020
  152. Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways. Regul Toxicol Pharmacol, 2020
  153. Effect of berberine on in vitro metabolism of sulfonylureas: A herb-drug interactions study. Rapid Commun Mass Spectrom, 2020
  154. Protective efficacy of Tinospora sinensis against streptozotocin induced pancreatic islet cell injuries of diabetic rats and its correlation to its phytochemical profiles. J Ethnopharmacol, 2020
  155. Berberine ameliorates renal impairment and inhibits podocyte dysfunction by targeting the phosphatidylinositol 3-kinase-protein kinase B pathway in diabetic rats. J Diabetes Investig, 2020
  156. Berberine attenuates olanzapine induced-metabolic syndrome. J Pak Med Assoc, 2019
  157. Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats. Diabetes Metab Syndr Obes, 2019
  158. Berberine Ameliorates Spatial Learning Memory Impairment and Modulates Cholinergic Anti-Inflammatory Pathway in Diabetic Rats. Front Pharmacol, 2019
  159. Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice. Biomed Pharmacother, 2019
  160. Berberine chloride ameliorated PI3K/Akt-p/SIRT-1/PTEN signaling pathway in insulin resistance syndrome induced in rats. J Food Biochem, 2019
  161. Amorphous solid dispersion of Berberine mitigates apoptosis via iPLA2β/Cardiolipin/Opa1 pathway in db/db mice and in Palmitate-treated MIN6 β-cells. Int J Biol Sci, 2019
  162. Metformin in contrast to berberine reversed arsenic-induced oxidative stress in mitochondria from rat pancreas probably via Sirt3-dependent pathway. J Biochem Mol Toxicol, 2019
  163. Glucose consumption assay discovers coptisine with beneficial effect on diabetic mice. Eur J Pharmacol, 2019
  164. Podoplanin mediates the renoprotective effect of berberine on diabetic kidney disease in mice. Acta Pharmacol Sin, 2019
  165. Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. Cell Death Dis, 2019
  166. Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice. Sci Rep, 2019
  167. Berberine ameliorates diabetic neuropathic pain in a rat model: involvement of oxidative stress, inflammation, and μ-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol, 2019
  168. A novel berberine-metformin hybrid compound exerts therapeutic effects on obese type 2 diabetic rats. Clin Exp Pharmacol Physiol, 2019
  169. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3. FASEB J, 2019
  170. Diversity of the Gut Microbiota in Dihydrotestosterone-Induced PCOS Rats and the Pharmacologic Effects of Diane-35, Probiotics, and Berberine. Front Microbiol, 2019
  171. Enhanced Anti-diabetic Effect of Berberine Combined With Timosaponin B2 in Goto-Kakizaki Rats, Associated With Increased Variety and Exposure of Effective Substances Through Intestinal Absorption. Front Pharmacol, 2019
  172. Berberine, a Traditional Chinese Medicine, Reduces Inflammation in Adipose Tissue, Polarizes M2 Macrophages, and Increases Energy Expenditure in Mice Fed a High-Fat Diet. Med Sci Monit, 2019
  173. Berberine suppresses the ectopic expression of miR-133a in endothelial cells to improve vascular dementia in diabetic rats. Clin Exp Hypertens, 2019
  174. SirT3 regulates diabetogenic effects caused by arsenic: An implication for mitochondrial complex II modification. Toxicol Lett, 2019
  175. Hypoglycemic Mechanism of the Berberine Organic Acid Salt under the Synergistic Effect of Intestinal Flora and Oxidative Stress. Oxid Med Cell Longev, 2018
  176. Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability. Molecules, 2018
  177. Restoration of GLP-1 secretion by Berberine is associated with protection of colon enterocytes from mitochondrial overheating in diet-induced obese mice. Nutr Diabetes, 2018
  178. Possible therapeutic potential of berberine in the treatment of STZ plus HFD-induced diabetic osteoporosis. Biomed Pharmacother, 2018
  179. Berberine Alleviates Tau Hyperphosphorylation and Axonopathy-Associated with Diabetic Encephalopathy via Restoring PI3K/Akt/GSK3β Pathway. J Alzheimers Dis, 2018
  180. Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats. Am J Physiol Heart Circ Physiol, 2018
  181. Berberine Protects against NEFA-Induced Impairment of Mitochondrial Respiratory Chain Function and Insulin Signaling in Bovine Hepatocytes. Int J Mol Sci, 2018
  182. Berberine alleviates adipose tissue fibrosis by inducing AMP-activated kinase signaling in high-fat diet-induced obese mice. Biomed Pharmacother, 2018
  183. Berberine Improves Cognitive Deficiency and Muscular Dysfunction via Activation of the AMPK/SIRT1/PGC-1a Pathway in Skeletal Muscle from Naturally Aging Rats. J Nutr Health Aging, 2018
  184. [Jatrorrhizine regulates GLUTs with multiple manners for hypoglycemic effect in insulin-resistance 3T3-L1 adipocytes]. Zhongguo Zhong Yao Za Zhi, 2018
  185. Improvement of intestinal transport, absorption and anti-diabetic efficacy of berberine by using Gelucire44/14: In vitro, in situ and in vivo studies. Int J Pharm, 2018
  186. Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. Biol Res, 2018
  187. Dai-Zong-Fang, A Traditional Chinese Herbal Formula, Ameliorates Insulin Resistance in db/db Mice. Front Physiol, 2018
  188. Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. Exp Clin Endocrinol Diabetes, 2018
  189. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. Biomed Pharmacother, 2018
  190. Effects of Berberine chloride on the liver of streptozotocin-induced diabetes in albino Wistar rats. Biomed Pharmacother, 2018
  191. Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21. Br J Pharmacol, 2018
  192. Berberine Improves Diabetic Encephalopathy Through the SIRT1/ER Stress Pathway in db/db Mice. Rejuvenation Res, 2018
  193. Berberine Ameliorates Diabetic Neuropathy: TRPV1 Modulation by PKC Pathway. Am J Chin Med, 2017
  194. Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes. Eur J Med Chem, 2017
  195. Berberine Inhibits Oxygen Consumption Rate Independent of Alteration in Cardiolipin Levels in H9c2 Cells. Lipids, 2017
  196. Protective role of berberine and Coptischinensis extract on T2MD rats and associated islet Rin‑5f cells. Mol Med Rep, 2017
  197. Berberine chloride ameliorates oxidative stress, inflammation and apoptosis in the pancreas of Streptozotocin induced diabetic rats. Biomed Pharmacother, 2017
  198. Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk. Biomed Pharmacother, 2017
  199. Comparative pharmacokinetics of six major bioactive components in normal and type 2 diabetic rats after oral administration of Sanhuang Xiexin Decoction extracts by UPLC-TQ MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci, 2017
  200. Berberine Ameliorates Diabetes-Associated Cognitive Decline through Modulation of Aberrant Inflammation Response and Insulin Signaling Pathway in DM Rats. Front Pharmacol, 2017
  201. Berberine reduced blood pressure and improved vasodilation in diabetic rats. J Mol Endocrinol, 2017
  202. Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice. Drug Des Devel Ther, 2017
  203. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism, 2017
  204. Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement. Biomed Pharmacother, 2017
  205. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord, 2017
  206. Berberine Attenuates Intestinal Mucosal Barrier Dysfunction in Type 2 Diabetic Rats. Front Pharmacol, 2017
  207. Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy. Mol Cell Endocrinol, 2017
  208. Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. Pharm Biol, 2017
  209. Nandinine, a Derivative of Berberine, Inhibits Inflammation and Reduces Insulin Resistance in Adipocytes via Regulation of AMP-Kinase Activity. Planta Med, 2017
  210. Antidiabetic potential of polyherbal formulation DB14201: Preclinical development, safety and efficacy studies. J Ethnopharmacol, 2017
  211. [Effect of protein intervention on amino acid metabolism spectrum of Qi and Yin deficiency type 2 diabetic rats]. Zhongguo Zhong Yao Za Zhi, 2016
  212. [Berberine regulates glycemia via local inhibition of intestinal dipeptidyl peptidase-Ⅳ]. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2016
  213. Modulation of Microbiota-Gut-Brain Axis by Berberine Resulting in Improved Metabolic Status in High-Fat Diet-Fed Rats. Obes Facts, 2016
  214. Identification and Verification of Potential Therapeutic Target Genes in Berberine-Treated Zucker Diabetic Fatty Rats through Bioinformatics Analysis. PLoS One, 2016
  215. [Effects and underlying mechanism of berberine on renal tubulointerstitial injury in diabetic rats]. Zhonghua Yi Xue Za Zhi, 2016
  216. Inhibition of M1 macrophage activation in adipose tissue by berberine improves insulin resistance. Life Sci, 2016
  217. [Berberine inhibits cardiac fibrosis of diabetic rats]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2016
  218. In Vivo Interrelationship between Insulin Resistance and Interferon Gamma Production: Protective and Therapeutic Effect of Berberine. Evid Based Complement Alternat Med, 2016
  219. Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. Mol Med Rep, 2016
  220. Berberine enhances antidiabetic effects and attenuates untoward effects of canagliflozin in streptozotocin-induced diabetic mice. Chin J Nat Med, 2016
  221. [Effects of berberine on mRNA expression levels of PPARγ and adipocytokines in insulin-resistant adipocytes]. Zhongguo Zhong Yao Za Zhi, 2016
  222. Berberine alleviates the cerebrovascular contractility in streptozotocin-induced diabetic rats through modulation of intracellular Ca²⁺ handling in smooth muscle cells. Cardiovasc Diabetol, 2016
  223. Antihyperglycemia and Antihyperlipidemia Effect of Protoberberine Alkaloids From Rhizoma Coptidis in HepG2 Cell and Diabetic KK-Ay Mice. Drug Dev Res, 2016
  224. Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway. PLoS One, 2016
  225. Berberine activates Nrf2 nuclear translocation and inhibits apoptosis induced by high glucose in renal tubular epithelial cells through a phosphatidylinositol 3-kinase/Akt-dependent mechanism. Apoptosis, 2016
  226. Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. Arch Iran Med, 2016
  227. Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signalling in diabetic rats. Br J Pharmacol, 2016
  228. Metabolomics Study of Type 2 Diabetes Mellitus and the AntiDiabetic Effect of Berberine in Zucker Diabetic Fatty Rats Using Uplc-ESI-Hdms. Phytother Res, 2016
  229. Neuroprotective effect of berberine is mediated by MAPK signaling pathway in experimental diabetic neuropathy in rats. Eur J Pharmacol, 2016
  230. Berberine Pretreatment Confers Cardioprotection Against Ischemia-Reperfusion Injury in a Rat Model of Type 2 Diabetes. J Cardiovasc Pharmacol Ther, 2016
  231. Berberine treatment attenuates the palmitate-mediated inhibition of glucose uptake and consumption through increased 1,2,3-triacyl-sn-glycerol synthesis and accumulation in H9c2 cardiomyocytes. Biochim Biophys Acta, 2016
  232. [Pharmacokinetic and pharmacodynamic characteristics of berberine and jateorhizine in Coptidis Rhizoma powder and their monomeric compounds in type 2 diabetic rats]. Zhongguo Zhong Yao Za Zhi, 2015
  233. [Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2015
  234. Protective effects of berberine on high fat-induced kidney damage by increasing serum adiponectin and promoting insulin sensitivity. Int J Clin Exp Pathol, 2015
  235. Effects of berberine and pomegranate seed oil on plasma phospholipid metabolites associated with risks of type 2 diabetes mellitus by U-HPLC/Q-TOF-MS. J Chromatogr B Analyt Technol Biomed Life Sci, 2015
  236. Berberine Reduces Neurotoxicity Related to Nonalcoholic Steatohepatitis in Rats. Evid Based Complement Alternat Med, 2015
  237. Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5'-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells. Eur J Pharmacol, 2015
  238. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep, 2015
  239. Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats. Eur J Pharmacol, 2015
  240. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World J Gastroenterol, 2015
  241. Berberine Attenuates Vascular Remodeling and Inflammation in a Rat Model of Metabolic Syndrome. Biol Pharm Bull, 2015
  242. Berberine Suppresses Adipocyte Differentiation via Decreasing CREB Transcriptional Activity. PLoS One, 2015
  243. Renoprotective effect of berberine on type 2 diabetic nephropathy in rats. Clin Exp Pharmacol Physiol, 2015
  244. Berberine nanosuspension enhances hypoglycemic efficacy on streptozotocin induced diabetic C57BL/6 mice. Evid Based Complement Alternat Med, 2015
  245. Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. Biomed Res Int, 2015
  246. Berberine improves kidney function in diabetic mice via AMPK activation. PLoS One, 2014
  247. Effects of combinations of Xiexin decoction constituents on diabetic nephropathy in rats. J Ethnopharmacol, 2014
  248. Shensong Yangxin Capsule prevents diabetic myocardial fibrosis by inhibiting TGF-β1/Smad signaling. J Ethnopharmacol, 2014
  249. Glucagon-induced angiogenesis and tumor growth through the HIF-1-VEGF-dependent pathway in hyperglycemic nude mice. Genet Mol Res, 2014
  250. Coptis chinensis alkaloids exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP-α and PPAR-γ. Fitoterapia, 2014
  251. Comparative metabolites in plasma and urine of normal and type 2 diabetic rats after oral administration of the traditional Chinese scutellaria-coptis herb couple by ultra performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2014
  252. Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine. BMC Complement Altern Med, 2014
  253. Intestinal absorption of berberine and 8-hydroxy dihydroberberine and their effects on sugar absorption in rat small intestine. J Huazhong Univ Sci Technolog Med Sci, 2014
  254. Berberine hydrochloride prevents postsurgery intestinal adhesion and inflammation in rats. J Pharmacol Exp Ther, 2014
  255. Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K-Akt signaling in diabetic rats. Apoptosis, 2014
  256. Synthesis and in vitro evaluation of 12-(substituted aminomethyl) berberrubine derivatives as anti-diabetics. Bioorg Med Chem Lett, 2014
  257. Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy. Mol Biol Rep, 2014
  258. Alkaloids from Coptis chinensis root promote glucose uptake in C2C12 myotubes. Fitoterapia, 2014
  259. Hypolipidemic effect of the Chinese polyherbal Huanglian Jiedu decoction in type 2 diabetic rats and its possible mechanism. Phytomedicine, 2014
  260. Pharmacokinetic comparisons of berberine and palmatine in normal and metabolic syndrome rats. J Ethnopharmacol, 2014
  261. Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats. Mol Neurobiol, 2014
  262. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int J Nanomedicine, 2013
  263. Improvement of superoxide dismutase and catalase in streptozotocin-nicotinamide-induced type 2-diabetes in mice by berberine and glibenclamide. Pharm Biol, 2013
  264. Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats. J Endocrinol, 2013
  265. The anti-diabetic effects and pharmacokinetic profiles of berberine in mice treated with Jiao-Tai-Wan and its compatibility. Phytomedicine, 2013
  266. Berberine improves insulin resistance in cardiomyocytes via activation of 5'-adenosine monophosphate-activated protein kinase. Metabolism, 2013
  267. Berberine ameliorates renal injury by regulating G proteins-AC- cAMP signaling in diabetic rats with nephropathy. Mol Biol Rep, 2013
  268. Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats. Mol Biol Rep, 2013
  269. Antihyperglycemic effect of the traditional Chinese scutellaria-coptis herb couple and its main components in streptozotocin-induced diabetic rats. J Ethnopharmacol, 2013
  270. [Regulatory effect of berberine on unbalanced expressions of renal tissue TGF-beta1/SnoN and smad signaling pathway in rats with early diabetic nephropathy]. Zhongguo Zhong Yao Za Zhi, 2012
  271. A preliminary investigation of the mechanisms underlying the effect of berberine in preventing high-fat diet-induced insulin resistance in rats. J Physiol Pharmacol, 2012
  272. Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking. Phytomedicine, 2012
  273. Anti-hyperglycemic effects and mechanism of traditional Chinese medicine Huanglian Wan in streptozocin-induced diabetic rats. J Ethnopharmacol, 2012
  274. Berberine inhibits mouse insulin gene promoter through activation of AMP activated protein kinase and may exert beneficial effect on pancreatic β-cell. Eur J Pharmacol, 2012
  275. Anti-diabetic effect of a traditional Chinese medicine formula. Food Funct, 2012
  276. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One, 2012
  277. Alteration of hepatic glutathione peroxidase and superoxide dismutase expression in streptozotocin-induced diabetic mice by berberine. Pharm Biol, 2012
  278. Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine, 2012
  279. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes, 2012
  280. Modulations of cytochrome P450 expression in diabetic mice by berberine. Chem Biol Interact, 2012
  281. Protective effect of berberine on serum glucose levels in non-obese diabetic mice. Int Immunopharmacol, 2012
  282. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim Biophys Acta, 2012
  283. Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice. Planta Med, 2012
  284. [Effect of berberine on expression of transforming growth factor-beta1 and type IV collagen proteins in mesangial cells of diabetic rats with nephropathy]. Zhongguo Zhong Yao Za Zhi, 2011
  285. Berberine improves glucose homeostasis in streptozotocin-induced diabetic rats in association with multiple factors of insulin resistance. ISRN Endocrinol, 2011
  286. [Effects of berberine on the pancreatic beta cell apoptosis in rats with insulin resistance]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2011
  287. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS One, 2011
  288. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One, 2011
  289. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol, 2011
  290. Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. Eur J Pharm Sci, 2011
  291. Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway. Endocr J, 2011
  292. [Effects of Ganoderma lucidum polysaccharides on advanced glycation end products and receptor of aorta pectoralis in T2DM rats]. Zhongguo Zhong Yao Za Zhi, 2011
  293. Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver x receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters. Biol Pharm Bull, 2011
  294. Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats. Eur J Pharmacol, 2011
  295. [Changes of metabolic indices caused by berberin and extract, obtained from the bark of Phellodendron lavalei, introduced in subtropic regions of Georgia, in streptozotocin induced diabetic rats]. Georgian Med News, 2011
  296. [Antidiabetic activity of berberin and extract, obtained from the bark of Phellodendron lavalei, introduced in subtropic regions of Georgia, in streptozotocin induced diabetic rats]. Georgian Med News, 2011
  297. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One, 2011
  298. Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. Behav Brain Res, 2011
  299. Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model. Phytother Res, 2011
  300. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism, 2011
  301. Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. Eur J Pharmacol, 2010
  302. [Hypoglycemic activity of berberin and extract obtained from the bark of Phellodendron lavalei, introduced in sub tropic areas of Georgia]. Georgian Med News, 2010
  303. Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. Endocr J, 2010
  304. 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Bioorg Med Chem, 2010
  305. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res, 2010
  306. Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine. Diabetes, 2010
  307. Berberine inhibits PTP1B activity and mimics insulin action. Biochem Biophys Res Commun, 2010
  308. [Controlling effect of berberine on in vitro synthesis and metabolism of steroid hormones in insulin resistant ovary]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2010
  309. [Effect of Ganoderma lucidum polysaccharides on hemodynamic and antioxidation in T2DM rats]. Zhongguo Zhong Yao Za Zhi, 2010
  310. Enhancement of sodium caprate on intestine absorption and antidiabetic action of berberine. AAPS PharmSciTech, 2010
  311. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol, 2010
  312. Berberine modulates insulin signaling transduction in insulin-resistant cells. Mol Cell Endocrinol, 2010
  313. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol, 2010
  314. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia, 2010
  315. [8-hydroxy-dihydroberberine ameliorated insulin resistance induced by high FFA and high glucose in 3T3-L1 adipocytes]. Yao Xue Xue Bao, 2009
  316. [Of berberine and puerarin on dexamethasone-induced insulin resistance in porcine ovarian thecal cells]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2009
  317. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur J Pharmacol, 2009
  318. Antihyperglycemic and antioxidant effect of Berberis aristata root extract and its role in regulating carbohydrate metabolism in diabetic rats. J Ethnopharmacol, 2009
  319. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab, 2009
  320. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J Endocrinol, 2009
  321. [Effects of berberine on expression of hepatocyte nuclear factor 4alpha and glucokinase activity in mouse primary hepatocytes]. Zhongguo Zhong Yao Za Zhi, 2008
  322. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res, 2008
  323. Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus. Chin Med J (Engl), 2008
  324. [Effects of huanglian jiedu decoction on the oxidative stress of liver mitochondria in insulin resistant Rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2008
  325. Comparison of the antidiabetic activity of Berberis lyceum root extract and berberine in alloxan-induced diabetic rats. Phytother Res, 2008
  326. Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J (Engl), 2008
  327. Effect of berberine on expression of hepatocyte nuclear factor-4alpha in rats with fructose-induced insulin resistance. J Huazhong Univ Sci Technolog Med Sci, 2008
  328. Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats. Pharmazie, 2008
  329. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull, 2008
  330. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Arch Biochem Biophys, 2008
  331. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes, 2008
  332. Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta. World J Gastroenterol, 2008
  333. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab, 2008
  334. Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae. Yao Xue Xue Bao, 2007
  335. [Molecular mechanism of berberine in improving insulin resistance induced by free fatty acid through inhibiting nuclear trascription factor-kappaB p65 in 3T3-L1 adipocytes]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2007
  336. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 2006
  337. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol, 2006
  338. [Effects of huanglian jiedu decoction on leptin and resistin in insulin resistive rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2006
  339. Hypoglycemic activity of jatrorrhizine. J Huazhong Univ Sci Technolog Med Sci, 2005
  340. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin, 2004
  341. [Effect of berberine on the differentiation of adipocyte]. Zhonghua Yi Xue Za Zhi, 2003
  342. [Experimental study on berberin raised insulin sensitivity in insulin resistance rat models]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 1997
  343. [Inhibitory effect of berberine on potassium channels in guinea pig ventricular myocytes]. Yao Xue Xue Bao, 1994
  344. [Determination of berberine in biological specimen by high performance TLC and fluoro-densitometric method]. Yao Xue Xue Bao, 1993
  345. [Effects of berberine on blood glucose regulation of normal mice]. Yao Xue Xue Bao, 1987
  346. [Studies on the hypoglycemic effect of Coptis chinensis and berberine]. Yao Xue Xue Bao, 1986
Lab studies 151
  1. Comparative Effects of Myo-Inositol, Metformin, Berberine, and Combination Therapy on Metabolic, Anthropometric and Hormonal Parameters in Women with Polycystic Ovary Syndrome: A 6-Month Observational Cohort Study. J Clin Med, 2026
  2. Development of Selenized Phytosomes for Sustained Release of Berberine and Synergistic Hypoglycemic Effect. Curr Pharm Des, 2026
  3. Dual pH/glucose-responsive berberine-loaded bioactive glass/carboxymethyl chitosan hydrogel for promoting diabetic wound healing. J Biomater Sci Polym Ed, 2026
  4. Berberine attenuates diabetic kidney injury via FOXO1/SP1-associated regulation of renal SGLT-2 expression. Chin Med, 2026
  5. Exploring the therapeutic response to sodium-glucose cotransporter-2 inhibition in INSR-related insulin resistance monogenic diabetes: case-based analysis and narrative review. Acta Diabetol, 2026
  6. Temporal-responsive hydrogels reprogramming energy metabolic pathway in the bone-angiogenic cascade for diabetic bone regeneration. Mater Today Bio, 2026
  7. Herbal Medicine and Metabolic Syndrome: Phytochemicals Targeting the Molecular Causes of Insulin Resistance and Related Comorbidities. Curr Diabetes Rev, 2026
  8. Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial. Diabetol Metab Syndr, 2026
  9. Berberine Regulates Hepatic Fatty Acid Metabolism via AMPK/SIRT1/PGC-1α Pathway. Chin J Integr Med, 2026
  10. Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control. Nat Metab, 2026
  11. Berberine Ameliorates Diabetic Kidney Disease by Modulating Macrophage Polarization via Inhibiting IL-17A Signaling. J Inflamm Res, 2026
  12. New multitarget antidiabetic potential agents based on sulfaguanidine: design, synthesis, and biological evaluation. RSC Adv, 2026
  13. Zhimu-Huangbai codecoction for the treatment of type II diabetes mellitus through its self-assembling nanoparticles. Chin Med, 2026
  14. Vanadyl Acetylacetonate and Berberine Synergistically Ameliorate Diabetes-induced Vascular Dysfunction and Reduce Endothelial Toxicity through ERK and Akt Regulation. Biol Trace Elem Res, 2026
  15. Mechanism of Jianpixiaoke Recipe in Treating Type 2 Diabetes Based on Network Pharmacology and Molecular Docking. Int J Endocrinol, 2025
  16. Exploration mechanisms of Coptis chinensis Franch. and Rehmannia glutinosa Libosch. against T2DM based on network pharmacology and molecular docking. Medicine (Baltimore), 2025
  17. Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycemic control. bioRxiv, 2025
  18. Synergistic potential of Berberine and Wogonin improved adipose inflammation and insulin resistance associated with obesity through HIF-α axis. Chin Med, 2025
  19. In silico evaluation of berberine and silymarin against metabolic targets: a rationale for OMICS technology-based co-formulation. In Silico Pharmacol, 2025
  20. Berberine: A Bitter Phytochemical With Diversely Sweet Therapeutic Properties. Nutr Rev, 2025
  21. Targeting inflammatory and insulin-regulatory proteins in type 2 diabetes mellitus: Insights from Argemone ochroleuca (sweet) via multi-omics and network pharmacology with experimental verification. Int J Biol Macromol, 2025
  22. Berberine inhibits high glucose-induced ferroptosis in retinal vascular endothelial cells: Mechanism and implications. Exp Eye Res, 2025
  23. [Berberine promotes expression of AQP4 in astrocytes by regulating production of miR-383-5p in HepG2 cell-derived exosomes under insulin resistance]. Zhongguo Zhong Yao Za Zhi, 2025
  24. A 30-Day Randomized Crossover Human Study on the Safety and Tolerability of a New Micellar Berberine Formulation with Improved Bioavailability. Metabolites, 2025
  25. The potential role and mechanism of Rhizoma Coptidis in prevention of diabetic encephalopathy: targeting sodium ion and channels. Front Pharmacol, 2025
  26. A Berberine Derivative for Treatment of Type 2 Diabetes. JAMA Netw Open, 2025
  27. Bioactive materials from berberine-treated human bone marrow mesenchymal stem cells accelerate tooth extraction socket healing through the jaw vascular unit. Sci China Life Sci, 2025
  28. In silico design and computational screening of berberine derivatives for potential antidiabetic activity through allosteric activation of the AMPK pathway. In Silico Pharmacol, 2025
  29. Berberine Ameliorates High-fat-induced Insulin Resistance in HepG2 Cells by Modulating PPARs Signaling Pathway. Curr Comput Aided Drug Des, 2025
  30. [Berberine regulates glucose and lipid metabolism via clock-controlled genes to ameliorate insulin resistance of hepatocytes]. Zhongguo Zhong Yao Za Zhi, 2024
  31. [Mechanism of Huangqi Simiao Decoction in treatment of type 2 diabetes mellitus based on network pharmacology and metabonomics]. Zhongguo Zhong Yao Za Zhi, 2024
  32. The improvement of modified Si-Miao granule on hepatic insulin resistance and glycogen synthesis in type 2 diabetes mellitus involves the inhibition of TNF-α/JNK1/IRS-2 pathway: network pharmacology, molecular docking, and experimental validation. Chin Med, 2024
  33. Charting Wellness in India: Piloting the iTHRIVE's Functional Nutrition Approach to Improve Glycaemic and Inflammatory Parameters in Prediabetes and Type 2 Diabetes Mellitus. Cureus, 2024
  34. Study of the antidiabetic mechanism of berberine compound on FOXO1 transcription factor through molecular docking and molecular dynamics simulations. J Mol Model, 2024
  35. Protective Effects of Bioactive Compound-Derived Nanoparticle Against Diabetic Retinopathy Through the Modulation of the NF-κB Signaling Pathway. ACS Omega, 2024
  36. Deciphering unique and shared interactions between the human gut microbiota and oral antidiabetic drugs. Imeta, 2024
  37. Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD. J Ethnopharmacol, 2024
  38. Bletilla striata Polysaccharide-/Chitosan-Based Self-Healing Hydrogel with Enhanced Photothermal Effect for Rapid Healing of Diabetic Infected Wounds via the Regulation of Microenvironment. Biomacromolecules, 2024
  39. Biochemical Investigation of Therapeutic Efficacy of Berberine-Enriched Extract in Streptozotocin-Induced Metabolic Impairment. ACS Omega, 2024
  40. Berberine modulates cardiovascular diseases as a multitarget-mediated alkaloid with insights into its downstream signals using in silico prospective screening approaches. Saudi J Biol Sci, 2024
  41. Huang-Lian-Jie-Du decoction drug-containing serum inhibits IL-1β secretion from D-glucose and PA induced BV2 cells via autophagy/NLRP3 signaling. J Ethnopharmacol, 2024
  42. Potential role of Akt in the regulation of fibroblast growth factor 21 by berberine. J Nat Med, 2024
  43. Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers. Pharmaceutics, 2023
  44. The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment. Biomedicines, 2023
  45. Commentary: Inhibitors of mitochondrial respiratory chain in the treatment of type 2 diabetes. Acta Pharm Sin B, 2023
  46. Liposome-Encapsulated Berberine Alleviates Liver Injury in Type 2 Diabetes via Promoting AMPK/mTOR-Mediated Autophagy and Reducing ER Stress: Morphometric and Immunohistochemical Scoring. Antioxidants (Basel), 2023
  47. Berberine Regulates GPX4 to Inhibit Ferroptosis of Islet β Cells. Planta Med, 2023
  48. Berberine chloride (dual topoisomerase I and II inhibitor) modulate mitochondrial uncoupling protein (UCP1) in molecular docking and dynamic with in-vitro cytotoxic and mitochondrial ATP production. J Biomol Struct Dyn, 2023
  49. Simiao Wan and its ingredients alleviate type 2 diabetes mellitus via IRS1/AKT2/FOXO1/GLUT2 signaling. Front Nutr, 2022
  50. Investigating the Mechanism of Rhizoma Coptidis-Eupatorium fortunei Medicine in the Treatment of Type 2 Diabetes Based on Network Pharmacology and Molecular Docking. Biomed Res Int, 2022
  51. A Composition of Phytonutrients for Glycemic and Weight Management. Nutrients, 2022
  52. The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial. Med J Islam Repub Iran, 2022
  53. The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial. Diabetol Metab Syndr, 2022
  54. Cellular and Molecular Mechanisms and Effects of Berberine on Obesity-Induced Inflammation. Biomedicines, 2022
  55. Purification, biochemical characterization, and DPP-IV and α-amylase inhibitory activity of Berberine from Cardiospermum halicacabum. J Mol Recognit, 2022
  56. Exploration of Isoquinoline Alkaloids as Potential Inhibitors against Human Islet Amyloid Polypeptide. ACS Chem Neurosci, 2022
  57. Berberine Improves TNF-α-Induced Hepatic Insulin Resistance by Targeting MEKK1/MEK Pathway. Inflammation, 2022
  58. Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study. Cureus, 2022
  59. Exploring the synergistic and complementary effects of berberine and paeoniflorin in the treatment of type 2 diabetes mellitus by network pharmacology. Eur J Pharmacol, 2022
  60. Measuring the Effects of Berberine on Serum Prooxidant-Antioxidant Balance in Metabolic Syndrome. Methods Mol Biol, 2022
  61. Uncoupling Protein 2 as a Pathogenic Determinant and Therapeutic Target in Cardiovascular and Metabolic Diseases. Curr Neuropharmacol, 2022
  62. Berberine Reduces Renal Cell Pyroptosis in Golden Hamsters with Diabetic Nephropathy through the Nrf2-NLRP3-Caspase-1-GSDMD Pathway. Evid Based Complement Alternat Med, 2021
  63. Boosting GLP-1 by Natural Products. Adv Exp Med Biol, 2021
  64. Discovery of the First in Class 9-N-Berberine Derivative as Hypoglycemic Agent with Extra-Strong Action. Pharmaceutics, 2021
  65. Berberine Potentiates Insulin Secretion and Prevents β-cell Dysfunction Through the miR-204/SIRT1 Signaling Pathway. Front Pharmacol, 2021
  66. Berberine Acts on C/EBPβ/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells. Front Endocrinol (Lausanne), 2021
  67. Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR. Exp Ther Med, 2021
  68. Berberine activates the β-catenin/TCF4 signaling pathway by down-regulating miR-106b to promote GLP-1 production by intestinal L cells. Eur J Pharmacol, 2021
  69. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health, 2021
  70. Berberine Ameliorates Hepatic Insulin Resistance by Regulating microRNA-146b/SIRT1 Pathway. Diabetes Metab Syndr Obes, 2021
  71. In-Vitro α-amylase, α-glucosidase Inhibitory Activities and In-Vivo Anti-Hyperglycemic Potential of Different Dosage Forms of Guduchi (Tinospora Cordifolia [Willd.] Miers) Prepared With Ayurvedic Bhavana Process. Front Pharmacol, 2021
  72. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol, 2021
  73. Beneficial Metabolic Effect of a Nutraceuticals Combination (Monacolin K, Yeasted Red Rice, Polyphenolic Extract of Annurca Apple and Berberine) on Acquired Hypercholesterolemia: A Prospective Analysis. Metabolites, 2021
  74. Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway. Biofactors, 2021
  75. TLC-MS Bioautography-Based Identification of Free-Radical Scavenging, α-Amylase, and α-Glucosidase Inhibitor Compounds of Antidiabetic Tablet BGR-34. ACS Omega, 2020
  76. Berberine reduces gut-vascular barrier permeability via modulation of ApoM/S1P pathway in a model of polymicrobial sepsis. Life Sci, 2020
  77. The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome. PLoS One, 2020
  78. Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle. Free Radic Biol Med, 2020
  79. An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia. Diabetes Metab Syndr Obes, 2020
  80. Combined Use of Astragalus Polysaccharide and Berberine Attenuates Insulin Resistance in IR-HepG2 Cells via Regulation of the Gluconeogenesis Signaling Pathway. Front Pharmacol, 2019
  81. Inhibitory effects of berberine on proinflammatory M1 macrophage polarization through interfering with the interaction between TLR4 and MyD88. BMC Complement Altern Med, 2019
  82. Berberine improves insulin resistance in adipocyte models by regulating the methylation of hypoxia-inducible factor-3α. Biosci Rep, 2019
  83. Novel berberine-based derivatives with potent hypoglycemic activity. Bioorg Med Chem Lett, 2019
  84. Vanadium compounds induced damage of human umbilical vein endothelial cells and the protective effect of berberine. Biometals, 2019
  85. Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review. Medicine (Baltimore), 2019
  86. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge. Colloids Surf B Biointerfaces, 2019
  87. Ameliorative Effect of Berberine on Neonatally Induced Type 2 Diabetic Neuropathy via Modulation of BDNF, IGF-1, PPAR-γ, and AMPK Expressions. Dose Response, 2019
  88. Berberine Influences Blood Glucose via Modulating the Gut Microbiome in Grass Carp. Front Microbiol, 2019
  89. Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Exp Ther Med, 2019
  90. Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients. J Res Med Sci, 2018
  91. [Differentiated hypoglycemic effects of baicalin, berberine and puerarin on insulin-resistance HepG2 cells]. Zhongguo Zhong Yao Za Zhi, 2018
  92. Berberine Ameliorates High Glucose-Induced Cardiomyocyte Injury via AMPK Signaling Activation to Stimulate Mitochondrial Biogenesis and Restore Autophagic Flux. Front Pharmacol, 2018
  93. Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3. Endocrine, 2018
  94. A 42-Markers Pharmacokinetic Study Reveals Interactions of Berberine and Glycyrrhizic Acid in the Anti-diabetic Chinese Medicine Formula Gegen-Qinlian Decoction. Front Pharmacol, 2018
  95. Metformin influences drug sensitivity in pancreatic cancer cells. Adv Biol Regul, 2018
  96. Berberine activates bitter taste responses of enteroendocrine STC-1 cells. Mol Cell Biochem, 2018
  97. Effect of new nutraceutical formulation with policosanol, berberine, red yeast rice, cassia nomame, astaxantine and Q10 coenzyme in patients with low-moderate dyslipidemia associated with intolerance to statins and metabolic syndrome. Minerva Cardioangiol, 2018
  98. Inhibition of mitochondrial complex I improves glucose metabolism independently of AMPK activation. J Cell Mol Med, 2018
  99. Variability in Potency Among Commercial Preparations of Berberine. J Diet Suppl, 2018
  100. Synthesis, Characterization, and Biological Evaluations of 1,3,5-Triazine Derivatives of Metformin Cyclization with Berberine and Magnolol in the Presence of Sodium Methylate. Molecules, 2017
  101. The Preconditioning of Berberine Suppresses Hydrogen Peroxide-Induced Premature Senescence via Regulation of Sirtuin 1. Oxid Med Cell Longev, 2017
  102. Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus. Iran J Basic Med Sci, 2017
  103. In vitro assessment of the glucose-lowering effects of berberrubine-9-O-β-D-glucuronide, an active metabolite of berberrubine. Acta Pharmacol Sin, 2017
  104. [Determination of six alkaloids in six types of Coptidis Rhizoma pieces by RP-HPLC and spectrum-effect relationships with anti-diabetes pharmacodynamics data]. Zhongguo Zhong Yao Za Zhi, 2016
  105. Effect of Diabetea tea ™ consumption on inflammatory cytokines and metabolic biomarkers in type 2 diabetes patients. J Ethnopharmacol, 2016
  106. Synthesis and hypoglycemic activity of 9-O-(lipophilic group substituted) berberine derivatives. Bioorg Med Chem Lett, 2016
  107. The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Evid Based Complement Alternat Med, 2016
  108. Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction. J Clin Diagn Res, 2016
  109. The roles of tricellular tight junction protein lipolysis-stimulated lipoprotein receptor in malignancy of human endometrial cancer cells. Oncotarget, 2016
  110. [Clinical characteristics and drug combination analysis in patients with inflammatory bowel disease based on real world HIS data of 14 758 cases]. Zhongguo Zhong Yao Za Zhi, 2016
  111. Berberine relieves insulin resistance via the cholinergic anti-inflammatory pathway in HepG2 cells. J Huazhong Univ Sci Technolog Med Sci, 2016
  112. [Regulations of berberine on gene expression of BMP4 transcriptional pathways to improve visceral white adipose tissues insulin resistance in type 2 diabetic hamsters]. Zhongguo Zhong Yao Za Zhi, 2016
  113. Drug approvals in India - Authors' reply. Lancet Diabetes Endocrinol, 2016
  114. Drug approvals in India. Lancet Diabetes Endocrinol, 2016
  115. Drug approvals in India. Lancet Diabetes Endocrinol, 2016
  116. Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography. Exp Ther Med, 2015
  117. Indian endocrinologists start debate on diabetes drug. BMJ, 2015
  118. The marketing of unproven drugs for diabetes and dyslipidaemia in India. Lancet Diabetes Endocrinol, 2015
  119. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochem Pharmacol, 2015
  120. Screening alpha-glucosidase and alpha-amylase inhibitors from natural compounds by molecular docking in silico. Biofactors, 2015
  121. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes, 2015
  122. Screening for potential -α -Glucosidase inhibitors in Coptis chinensis franch extract using ultrafiltration LC-ESI-MSn. Pak J Pharm Sci, 2014
  123. Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injury. PLoS One, 2014
  124. Dietary and nutraceutical approach to type 2 diabetes. Arch Med Sci, 2014
  125. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability. Int J Pharm, 2014
  126. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol, 2013
  127. Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function. Biol Pharm Bull, 2013
  128. Development of a cell-based high-throughput peroxisome proliferator-activated receptors (PPARs) screening model and its application for evaluation of the extracts from Rhizoma Coptis. J Asian Nat Prod Res, 2013
  129. Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux. Metabolism, 2013
  130. Mitochondrial inhibitor as a new class of insulin sensitizer. Acta Pharm Sin B, 2012
  131. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes, 2012
  132. Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis. Mol Cell Endocrinol, 2012
  133. Possible therapeutic potential of berberine in diabetic osteopathy. Med Hypotheses, 2012
  134. Promotion of adiponectin multimerization by emodin: a novel AMPK activator with PPARγ-agonist activity. J Cell Biochem, 2012
  135. Berberine acutely inhibits the digestion of maltose in the intestine. J Ethnopharmacol, 2012
  136. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med, 2012
  137. The Effects of Berberis vulgaris Fruit Extract on Serum Lipoproteins, apoB, apoA-I, Homocysteine, Glycemic Control and Total Antioxidant Capacity in Type 2 Diabetic Patients. Iran J Pharm Res, 2012
  138. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol, 2012
  139. Adiponectin self-regulates its expression and multimerization in adipose tissue: an autocrine/paracrine mechanism? Med Hypotheses, 2012
  140. Challenges in Drug Discovery for Thiazolidinedione Substitute. Yao Xue Xue Bao, 2011
  141. Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes. FEBS Lett, 2011
  142. Berberine reduces insulin resistance: the roles for glucocorticoid receptor and aryl hydrocarbon receptor. Fertil Steril, 2011
  143. Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. Inflammation, 2011
  144. Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism. Evid Based Complement Alternat Med, 2011
  145. Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. Fertil Steril, 2011
  146. Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells. Acta Pharmacol Sin, 2010
  147. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions. Metabolism, 2009
  148. Docking simulations and in vitro assay unveil potent inhibitory action of papaverine against protein tyrosine phosphatase 1B. Biol Pharm Bull, 2009
  149. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. Cardiovasc Res, 2009
  150. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism, 2009
  151. [Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research]. Zhong Xi Yi Jie He Za Zhi, 1988
Reviews 159
  1. Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular-Kidney-Metabolic Disease: A Narrative Review. Pharmaceuticals (Basel), 2026
  2. Plant-Derived Control of Postprandial Glycemia: α-Amylase, α-Glucosidase, and the Incretin-DPP-4 Interface. Pharmaceuticals (Basel), 2026
  3. The Therapeutic Potential of Berberine in Treating Diabetes and Its Complications: Molecular Mechanisms and Future Perspectives. Am J Chin Med, 2026
  4. Harnessing Medicinal Plants Through Advanced Drug Delivery: A New Era in Type 2 Diabetes Management. Pharmaceutics, 2026
  5. Berberine as a multitarget modulator of metabolic inflammation: molecular mechanisms, circadian regulation, and translational perspectives. Front Pharmacol, 2026
  6. [Research progress on traditional Chinese medicine in prevention and treatment of metabolic diseases via SIRT1/AMPK signaling pathway]. Zhongguo Zhong Yao Za Zhi, 2026
  7. Comparative Efficacy of Herbal Products on Metabolic Parameters in Metabolic-Dysfunction Associated Liver Disease: A Systematic Review and Network Meta-Analysis. Gastro Hep Adv, 2026
  8. Metabolic and Anti-Inflammatory Effects of Berberine-Rationale for Its Therapeutic Potential in Polycystic Ovary Syndrome. Int J Mol Sci, 2026
  9. Branched-chain amino acid metabolism and macrophage polarization: potential regulatory nodes and therapeutic targets in diabetes-associated metabolic inflammation. Front Cell Infect Microbiol, 2026
  10. Neuro-metabolic ageing drives diabetes-associated neurodegeneration: A geroscience and network pharmacology perspective. Ageing Res Rev, 2026
  11. "Envbiotics" -- a novel framework for microbiota-targeted therapeutic strategies in type 2 diabetes mellitus. Front Endocrinol (Lausanne), 2026
  12. Management of Type 2 Diabetes Mellitus: Targeting Gut Microbiome Therapy. Am J Chin Med, 2026
  13. Dihydroberberine in metabolic disorders: Bioavailability, molecular mechanisms, toxicology, and future perspectives. Food Chem Toxicol, 2026
  14. TCM-based natural products in type 2 diabetes: a comprehensive review of bioactive compounds and molecular mechanisms. Mol Divers, 2026
  15. Gut microbiome-blood cholesterol crosstalk: towards personalized strategies for dyslipidemia. Folia Microbiol (Praha), 2026
  16. Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions. Food Sci Nutr, 2026
  17. Research Progress of Natural Compounds in the Treatment of Diabetes and Its Complications. Phytother Res, 2026
  18. Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Front Pharmacol, 2026
  19. An overview on phytotherapeutics for metabolic syndrome: A journey from traditional knowledge to modern clinical validation. J Diabetes Metab Disord, 2026
  20. Harnessing Phytochemicals and Nanotechnology Synergy for Molecular, Epigenetic, and Microbiota-Driven Regulation in Type 2 Diabetes Mellitus. Pharmaceutics, 2026
  21. AMPK as a central regulator of metabolic memory: mechanisms and therapeutic opportunities. J Diabetes Metab Disord, 2026
  22. FOXO: a key target in regulating aging and age-related diseases. Biogerontology, 2026
  23. A comprehensive compendium of berberine: sources, chemistry, and pharmacological activities. J Sci Food Agric, 2026
  24. Mechanisms of efficacy of drug therapy in type 2 diabetes: the role of microbiomes. Minerva Endocrinol (Torino), 2026
  25. Epigenetic repurposing of carbohydrate metabolic inhibitors for insulin resistance: targeting DNMT1 and HDAC3 for β-cell restoration. Front Epigenet Epigenom, 2025
  26. Pharmacological advances in multi-targeted strategies for type 2 diabetes mellitus: a systematic perspective based on traditional Chinese medicine. Front Pharmacol, 2025
  27. Beneficial effects of berberine in the treatment of diabetes and its complications. Front Pharmacol, 2025
  28. Berberine: A Rising Star in the Management of Type 2 Diabetes-Novel Insights into Its Anti-Inflammatory, Metabolic, and Epigenetic Mechanisms. Pharmaceuticals (Basel), 2025
  29. Targeting the TLR4 axis with microbiota-oriented interventions and innovations in diabetes therapy: a narrative review. Front Immunol, 2025
  30. A review of the traditional uses, chemical compounds, pharmacological effects and modern clinical applications of Dahuang Huanglian Xiexin Decoction. Fitoterapia, 2025
  31. Botanical Antinutrients as Natural Modulators of Postprandial Hyperglycemia and Hyperlipidemia: A Narrative Review. Phytother Res, 2025
  32. Landscape of Berberine Targets: A Potential Pharmacological Insight for Heart Failure Treatment. J Cardiovasc Pharmacol, 2025
  33. A comprehensive review of recent advances in the extraction and therapeutic potential of berberine. RSC Adv, 2025
  34. Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives. Int J Mol Sci, 2025
  35. Common mechanisms of Gut microbe-based strategies for the treatment of intestine-related diseases: based on multi-target interactions with the intestinal barrier. Cell Commun Signal, 2025
  36. The Role of Nutraceuticals and Probiotics in Addition to Lifestyle Intervention in the Management of Childhood Obesity-Part 1: Metabolic Changes. Nutrients, 2025
  37. Endocrine regulation of metabolic crosstalk between liver and brown adipose tissue by natural active ingredients. Int J Obes (Lond), 2025
  38. Natural small molecules regulating the mitophagy pathway counteract the pathogenesis of diabetes and chronic complications. Front Pharmacol, 2025
  39. Berberis aristata DC. (Indian barberry): Current insight into botanical, phytochemical, and pharmacological aspects, pharmacokinetics, safety of use and modern therapeutic applications. Fitoterapia, 2025
  40. Nutrients and Natural Substances for Hypoglycemic Effects and Management in Diabetic Retinopathy. Nutrients, 2025
  41. Comprehensive treatment of diabetic endothelial dysfunction based on pathophysiological mechanism. Front Med (Lausanne), 2025
  42. Unveiling the therapeutic potential of berberine: its therapeutic role and molecular mechanisms in kidney diseases. Front Pharmacol, 2025
  43. Natural compounds in the management of polycystic ovary syndrome: a comprehensive review of hormonal regulation and therapeutic potential. Front Nutr, 2025
  44. Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease. Pharmaceuticals (Basel), 2025
  45. Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent. Pharmaceuticals (Basel), 2025
  46. Herbal Approaches to Diabetes Management: Pharmacological Mechanisms and Omics-Driven Discoveries. Phytother Res, 2025
  47. Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol, 2024
  48. A Descriptive Review of the Antioxidant Effects and Mechanisms of Action of Berberine and Silymarin. Molecules, 2024
  49. Protein Kinases in Obesity, and the Kinase-Targeted Therapy. Adv Exp Med Biol, 2024
  50. The therapeutic potential of typical plant-derived compounds for the management of metabolic disorders. Phytother Res, 2024
  51. Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies. Front Nutr, 2024
  52. Berberine: A Multi-Target Natural PCSK9 Inhibitor with the Potential to Treat Diabetes, Alzheimer's, Cancer and Cardiovascular Disease. Curr Rev Clin Exp Pharmacol, 2024
  53. Berberine prevents NAFLD and HCC by modulating metabolic disorders. Pharmacol Ther, 2024
  54. Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review. Arch Physiol Biochem, 2024
  55. Flavonoids, Isoflavonoids and others Bioactives for Insulin Sensitizations. Curr Diabetes Rev, 2024
  56. A Mechanistic Review on How Berberine Use Combats Diabetes and Related Complications: Molecular, Cellular, and Metabolic Effects. Pharmaceuticals (Basel), 2023
  57. Alkaloids as Promising Agents for the Management of Insulin Resistance: A Review. Curr Pharm Des, 2023
  58. Addressing the preventive and therapeutic perspective of berberine against diabetes. Heliyon, 2023
  59. Phytochemicals for the treatment of metabolic diseases: Evidence from clinical studies. Biomed Pharmacother, 2023
  60. Berberine and Its Study as an Antidiabetic Compound. Biology (Basel), 2023
  61. A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention. Molecules, 2023
  62. Role of Fenugreek, Cinnamon, Curcuma longa, Berberine and Momordica charantia in Type 2 Diabetes Mellitus Treatment: A Review. Pharmaceuticals (Basel), 2023
  63. Natural bioactive compounds in Alzheimer's disease: From the perspective of type 3 diabetes mellitus. Front Aging Neurosci, 2023
  64. A review of patent literature on the regulation of glucose metabolism by six phytocompounds in the management of diabetes mellitus and its complications. J Integr Med, 2023
  65. A Review of Fibraurea tinctoria and Its Component, Berberine, as an Antidiabetic and Antioxidant. Molecules, 2023
  66. Antidiabetic Phytocompounds Acting as Glucose Transport Stimulators. Endocr Metab Immune Disord Drug Targets, 2023
  67. Effects of Berberine against Pancreatitis and Pancreatic Cancer. Molecules, 2022
  68. Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus. Front Endocrinol (Lausanne), 2022
  69. The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Front Cell Infect Microbiol, 2022
  70. Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends. Molecules, 2022
  71. Anti-Hyperglycemic Agents in the Adjuvant Treatment of Sepsis: Improving Intestinal Barrier Function. Drug Des Devel Ther, 2022
  72. Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease. Molecules, 2022
  73. Maintaining Effective Beta Cell Function in the Face of Metabolic Syndrome-Associated Glucolipotoxicity-Nutraceutical Options. Healthcare (Basel), 2021
  74. It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them? Int J Mol Sci, 2021
  75. Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action. Am J Chin Med, 2021
  76. The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharm Sin B, 2021
  77. Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction. Int J Mol Sci, 2021
  78. A spotlight on underlying the mechanism of AMPK in diabetes complications. Inflamm Res, 2021
  79. Modern computational intelligence based drug repurposing for diabetes epidemic. Diabetes Metab Syndr, 2021
  80. Berberine for bone regeneration: Therapeutic potential and molecular mechanisms. J Ethnopharmacol, 2021
  81. Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia. Pharmacol Res, 2021
  82. Constituents, Pharmacokinetics, and Pharmacology of Gegen-Qinlian Decoction. Front Pharmacol, 2021
  83. Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview. Eur J Med Chem, 2021
  84. Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease. Mini Rev Med Chem, 2021
  85. Effect and mechanism of berberine against polycystic ovary syndrome. Biomed Pharmacother, 2021
  86. Impacts of Selected Dietary Nutrient Intakes on Skeletal Muscle Insulin Sensitivity and Applications to Early Prevention of Type 2 Diabetes. Adv Nutr, 2021
  87. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. Biomed Pharmacother, 2021
  88. Berberine in the Treatment of Diabetes Mellitus: A Review. Endocr Metab Immune Disord Drug Targets, 2021
  89. Protective and therapeutic effects of natural products against diabetes mellitus via regenerating pancreatic β-cells and restoring their dysfunction. Phytother Res, 2021
  90. Natural Alkaloids and Diabetes Mellitus: A Review. Endocr Metab Immune Disord Drug Targets, 2021
  91. Effects of Berberine on the Gastrointestinal Microbiota. Front Cell Infect Microbiol, 2020
  92. Medicinal plants in the adjunctive treatment of patients with type-1 diabetes: a systematic review of randomized clinical trials. J Diabetes Metab Disord, 2020
  93. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed Pharmacother, 2020
  94. Nano-based delivery systems for berberine: A modern anti-cancer herbal medicine. Colloids Surf B Biointerfaces, 2020
  95. Therapeutic application of nutraceuticals in diabetic nephropathy: Current evidence and future implications. Diabetes Metab Res Rev, 2020
  96. The Quest to Enhance the Efficacy of Berberine for Type-2 Diabetes and Associated Diseases: Physicochemical Modification Approaches. Biomedicines, 2020
  97. Rhizoma Coptidis for Alzheimer's Disease and Vascular Dementia: A Literature Review. Curr Vasc Pharmacol, 2020
  98. Plant-derived natural agents as dietary supplements for the regulation of glycosylated hemoglobin: A review of clinical trials. Clin Nutr, 2020
  99. Nanoformulations of natural products for management of metabolic syndrome. Int J Nanomedicine, 2019
  100. [Molecular mechanisms of insulin resistance and interventional effects of Chinese herbal medicine]. Zhongguo Zhong Yao Za Zhi, 2019
  101. Investigating functional properties of barberry species: an overview. J Sci Food Agric, 2019
  102. The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease. High Blood Press Cardiovasc Prev, 2019
  103. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol, 2019
  104. Activation of AMPK by Medicinal Plants and Natural Products: Its Role in Type 2 Diabetes Mellitus. Mini Rev Med Chem, 2019
  105. Natural Alkaloids Intervening the Insulin Pathway: New Hopes for Anti-Diabetic Agents? Curr Med Chem, 2019
  106. Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action. Diabetes Metab Syndr Obes, 2018
  107. Nutritional Modulation of AMPK-Impact upon Metabolic-Inflammation. Int J Mol Sci, 2018
  108. Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes. Expert Opin Pharmacother, 2018
  109. Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? Anticancer Res, 2018
  110. Nano strategies for berberine delivery, a natural alkaloid of Berberis. Biomed Pharmacother, 2018
  111. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. Oncotarget, 2018
  112. Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products. Curr Med Chem, 2018
  113. New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome. Cureus, 2017
  114. Rhizoma Coptidis and Berberine as a Natural Drug to Combat Aging and Aging-Related Diseases via Anti-Oxidation and AMPK Activation. Aging Dis, 2017
  115. New Insights into the Mechanisms of Chinese Herbal Products on Diabetes: A Focus on the "Bacteria-Mucosal Immunity-Inflammation-Diabetes" Axis. J Immunol Res, 2017
  116. Uncoupling Protein 2: A Key Player and a Potential Therapeutic Target in Vascular Diseases. Oxid Med Cell Longev, 2017
  117. [Research progress of berberine in treatment of diabetic kidney disease]. Zhongguo Zhong Yao Za Zhi, 2017
  118. [Pathogenesis and treatment of insulin resistance in chronic kidney disease and interventional effects of Chinese herbal medicine]. Zhongguo Zhong Yao Za Zhi, 2017
  119. Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease. Curr Pharm Des, 2017
  120. [Berberine regulates type 2 diabetes mellitus related with insulin resistance]. Zhongguo Zhong Yao Za Zhi, 2017
  121. Nutraceutical approaches to metabolic syndrome. Ann Med, 2017
  122. A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iran J Basic Med Sci, 2017
  123. Dietary Factors Promoting Brown and Beige Fat Development and Thermogenesis. Adv Nutr, 2017
  124. Mode of action of berberine on lipid metabolism: a new-old phytochemical with clinical applications? Curr Opin Lipidol, 2017
  125. Chinese Herbal Medicine for the Optimal Management of Polycystic Ovary Syndrome. Am J Chin Med, 2017
  126. Non-coding RNAs and Berberine: A new mechanism of its anti-diabetic activities. Eur J Pharmacol, 2017
  127. Rhizoma Coptidis: A Potential Cardiovascular Protective Agent. Front Pharmacol, 2016
  128. The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. Molecules, 2016
  129. Berberine and Its Role in Chronic Disease. Adv Exp Med Biol, 2016
  130. Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders. Curr Med Chem, 2016
  131. Functional food red yeast rice (RYR) for metabolic syndrome amelioration: a review on pros and cons. World J Microbiol Biotechnol, 2016
  132. Role of phytochemicals in the management of metabolic syndrome. Phytomedicine, 2016
  133. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. Atherosclerosis, 2015
  134. [Effect of berberine in treating type 2 diabetes mellitus and complications and its relevant mechanisms]. Zhongguo Zhong Yao Za Zhi, 2015
  135. Red Yeast Rice Plus Berberine: Practical Strategy for Promoting Vascular and Metabolic Health. Altern Ther Health Med, 2015
  136. Natural Products for the Treatment of Type 2 Diabetes Mellitus. Planta Med, 2015
  137. Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms. Eur J Pharmacol, 2015
  138. Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol, 2015
  139. Potential benefits of berberine in the management of perimenopausal syndrome. Oxid Med Cell Longev, 2015
  140. Therapeutic potential of berberine against neurodegenerative diseases. Sci China Life Sci, 2015
  141. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem Cell Biol, 2015
  142. Learning from berberine: Treating chronic diseases through multiple targets. Sci China Life Sci, 2015
  143. [Progress of berberine for treatment of type 2 diabetes]. Zhongguo Zhong Yao Za Zhi, 2014
  144. Efficacy of polyphenolic ingredients of Chinese herbs in treating dyslipidemia of metabolic syndromes. J Integr Med, 2014
  145. Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. Curr Top Med Chem, 2014
  146. AMPK activation--protean potential for boosting healthspan. Age (Dordr), 2014
  147. Nutraceuticals for metabolic syndrome management: from laboratory to benchside. Curr Vasc Pharmacol, 2014
  148. GPR40: a therapeutic target for mediating insulin secretion (review). Int J Mol Med, 2012
  149. Traditional Japanese herbal (kampo) medicines and treatment of ocular diseases: a review. Am J Chin Med, 2012
  150. Antidiabetic properties of berberine: from cellular pharmacology to clinical effects. Hosp Pract (1995), 2012
  151. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med Sci Monit, 2011
  152. Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr, 2011
  153. Diabetes is an inflammatory disease: evidence from traditional Chinese medicines. Diabetes Obes Metab, 2011
  154. [Advances of the mechanism study on berberine in the control of blood glucose and lipid as well as metabolism disorders]. Yao Xue Xue Bao, 2010
  155. Targeting metabolic syndrome: candidate natural agents. J Diabetes, 2010
  156. Role of endothelin receptor A and NADPH oxidase in vascular abnormalities. Vasc Health Risk Manag, 2010
  157. Advance of studies on anti-atherosclerosis mechanism of berberine. Chin J Integr Med, 2010
  158. [Advance on study in anti-atherosclerosis mechanism of berberine]. Zhongguo Zhong Yao Za Zhi, 2008
  159. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets, 2008
Other papers, not yet read by us 79
  1. Diet-driven cardiometabolic dysfunction as a potential amplifier of antimicrobial resistance: mechanistic evidence, gut resistome ecology, and dual-action nutraceutical interventions. Front Public Health, 2026
  2. Coptidis Rhizoma for Obesity, Diabetes, and Dyslipidemia: An Integrated Meta-Analysis and In Silico Study. Int J Mol Sci, 2026
  3. Effects of Berberine, White Mulberry Leaf Extract and Chromium Picolinate on Body Composition and Insulin Resistance in Adults with Obesity: A Randomized Controlled Trial. Nutrients, 2026
  4. Effects of a Multi-Component Nutraceutical (NUT2) on the Lipid Profile in Adults with Low-to-Moderate Cardiovascular Risk: A Randomized Placebo-Controlled Trial. Nutrients, 2026
  5. Defined Natural Products as Adjunctive Therapies: Evidence-Gated Polypharmacology Across Molecular Targets, Human Exposure, Clinical Signals, and Safety Boundaries. Int J Mol Sci, 2026
  6. Berberine Poisoning with Polymorphic Ventricular Tachycardia: A Case Report. Clin Pract Cases Emerg Med, 2026
  7. Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis. Front Psychiatry, 2026
  8. Considerations for Dietary Supplements after GLP-1RA Treatment: A Narrative Review. J Nutr, 2026
  9. Decoding polycystic ovary syndrome: an integrated review of epidemiology, molecular mechanisms, animal models, and the expanding therapeutic landscape. Naunyn Schmiedebergs Arch Pharmacol, 2026
  10. Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case-control study. Front Endocrinol (Lausanne), 2026
  11. Perfect Partner for a Dietary Alkaloid: Dual Role of Coptis chinensis Polysaccharide in Berberine Taste Masking and Immune Amplification. Plant Foods Hum Nutr, 2026
  12. Dual-targeting strategies for cancer and diabetes: Converging pharmacological pathways and repurposed therapies. Mol Aspects Med, 2026
  13. [Shared Therapeutic Targets of Obesity and Type 2 Diabetes Mellitus and the Intervention Mechanisms of Chinese Herbal Components]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2025
  14. Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research. Front Pharmacol, 2025
  15. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Front Pharmacol, 2025
  16. Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia, and Glycemic Response Improvement in a 60-year-Old Male with Metabolic Syndrome Through a Personalized Six-Month Nutraceutical/Diet Protocol: A Case Report. Altern Ther Health Med, 2025
  17. Breaking the vicious cycle: bitter compounds targeting metabolic defects and inflammation in Alzheimer's disease. Am J Physiol Endocrinol Metab, 2025
  18. Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-Analysis. Phytother Res, 2025
  19. Obesity: pathophysiology and therapeutic interventions. Mol Biomed, 2025
  20. HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clin Mol Hepatol, 2025
  21. Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review. Nutrients, 2025
  22. Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes. Physiol Rep, 2024
  23. Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study. Nutrients, 2024
  24. [Investigation of the effects and mechanisms of berberine on a mouse model of polycystic ovary syndrome: based on intestinal flora analysis]. Zhonghua Fu Chan Ke Za Zhi, 2024
  25. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med, 2024
  26. The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials. Clin Ther, 2024
  27. Revealing the improvement of diabetes by Si Wei Jiang Huang Tang San through ERK/HIF1α signaling pathway via network pharmacology. J Ethnopharmacol, 2024
  28. Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection. Int J STD AIDS, 2023
  29. Berberine and health outcomes: An umbrella review. Phytother Res, 2023
  30. The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis. Front Nutr, 2022
  31. Berberine in Non-Alcoholic Fatty Liver Disease-A Review. Nutrients, 2022
  32. Effects of Berberine Plus Inulin on Diabetes Care in Patients With Latent Autoimmune Diabetes in Adults: Protocol for a Randomized Controlled Trial. Front Endocrinol (Lausanne), 2022
  33. The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials. Inflammopharmacology, 2022
  34. Dietary supplements in therapy to support weight reduction in obese patients. Acta Sci Pol Technol Aliment, 2022
  35. Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. Psychiatry Clin Neurosci, 2022
  36. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study. Gut Microbes, 2022
  37. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients, 2021
  38. Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study. Nutrients, 2021
  39. Berberine is an insulin secretagogue targeting the KCNH6 potassium channel. Nat Commun, 2021
  40. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun, 2021
  41. Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial. Nutrients, 2021
  42. Medicinal Plants and Phytochemicals Regulating Insulin Resistance and Glucose Homeostasis in Type 2 Diabetic Patients: A Clinical Review. Adv Exp Med Biol, 2021
  43. Efficacy and Safety of Armolipid Plus®: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Nutrients, 2021
  44. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biol Sex Differ, 2021
  45. Remission of new-onset type 2 diabetes mellitus in an adolescent using an integrative medicine approach: A case report. J Integr Med, 2021
  46. Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine. Endocr Metab Immune Disord Drug Targets, 2021
  47. The effect and safety of Berberine on polycystic ovary syndrome: a systematic review. J Obstet Gynaecol, 2021
  48. The effect of Berberine on weight loss in order to prevent obesity: A systematic review. Biomed Pharmacother, 2020
  49. Role of a berberine-based nutritional supplement in reducing diarrhea in subjects with functional gastrointestinal disorders. Minerva Gastroenterol Dietol, 2020
  50. The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension. High Blood Press Cardiovasc Prev, 2019
  51. Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. Lipids Health Dis, 2019
  52. Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Phytother Res, 2019
  53. Polyherbal dietary supplementation for prediabetic adults: study protocol for a randomized controlled trial. Trials, 2019
  54. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. Am J Physiol Endocrinol Metab, 2019
  55. [Effects of berberine on the serum cystatin C levels and urine albumin/creatine ratio in patients with type 2 diabetes mellitus]. Zhonghua Yi Xue Za Zhi, 2018
  56. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine, 2018
  57. Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. High Blood Press Cardiovasc Prev, 2018
  58. First case of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) due to Berberine, an over-the-counter herbal glycemic control agent. Int J Dermatol, 2018
  59. Effectiveness and safety of bifidobacteria and berberine in people with hyperglycemia: study protocol for a randomized controlled trial. Trials, 2018
  60. Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in diabetic patients with dyslipidemia. Acta Biomed, 2018
  61. A Polyphenol-Based Multicomponent Nutraceutical in Dysmetabolism and Oxidative Stress: Results from a Pilot Study. J Diet Suppl, 2018
  62. Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. J Biol Regul Homeost Agents, 2017
  63. Adipose Tissue-Specialized Immunologic Features Might Be the Potential Therapeutic Target of Prospective Medicines for Obesity. J Diabetes Res, 2017
  64. The effect of berberine on insulin resistance in women with polycystic ovary syndrome: detailed statistical analysis plan (SAP) for a multicenter randomized controlled trial. Trials, 2016
  65. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med, 2016
  66. [Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2016
  67. The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res, 2016
  68. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One, 2015
  69. Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. Nutr J, 2015
  70. Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial. High Blood Press Cardiovasc Prev, 2015
  71. Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial. Trials, 2013
  72. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord, 2013
  73. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther, 2012
  74. Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome. Nutr Metab Cardiovasc Dis, 2012
  75. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol, 2012
  76. [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. Zhongguo Zhong Yao Za Zhi, 2011
  77. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther, 2011
  78. Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome. Nutr Res, 2011
  79. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis, 2010

Other conditions Berberine has been studied for

Checked against PubMed on 2026-10-28. Everything we know about Berberine